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Abstract 
 
Computational Studies of the HIV-1 Protease Dimer Interface 
by 
Jerome J. Quintero 
 
 
Chair:  Heather A. Carlson 
 
 
HIV-1 protease (HIVp) is one of four major drug targets to prevent 
propagation of the infectious HIV virion.  Currently, all ten marketed HIVp 
drugs are inhibitors that target the HIVp active site.  However, these drug 
therapies provide selective pressure resulting in mutations of the protease that 
escape drug efficacy.  Consequently, the development of inhibitors of HIVp that 
have new modes of action is necessary.  The dimer interface is an attractive 
target due to its highly conserved nature and its importance in forming an active 
enzyme. 
Until now, all dissociative inhibitors were created by mimicking residues 
at the dimer interface, and resulted in several non-drug-like compounds.  
However, we created several receptor-based pharmacophore models of the HIVp 
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dimer interface, using ensembles of multiple protein structures (MPS).  The MPS 
method was used to map the dimer interface with a series of small-molecule 
probes – methanol, ethane, and benzene.  The maps were translated into 
pharmacophore models which were used to filter in silico, three-dimensional 
library of small molecules.  The MPS method identified several novel small-
molecule inhibitors capable of inhibiting dimerization, with several compounds 
characterized with less than 50 µM-level affinity.  In the clinically relevant 
multi-drug resistant form of HIVp, these compounds maintained dissociative 
inhibition with nearly identical inhibition rates.  Zhang-Poorman kinetic analysis 
verified the small molecules inhibit HIVp in a dissociative manner. 
In addition to creating novel inhibitors, we modeled the protein-ligand 
interaction of known dissociative inhibitors using Langevin Dynamics.  Ten, 10-
ns simulations were initiated based on the hypothetical mechanism of ligand 
binding, but the dynamics simulations showed that the complex was unstable.  
Although the simulations did not result in a clear mechanism for protein-ligand 
binding, of the known dimerization inhibitors, they did demonstrate the entropic 
penalty of the proposed binding mechanism is unfavorable. 
Finally, we propose to use hydrogen/deuterium exchange (HDX) - mass 
spectrometry techniques to obtain new structural information and further 
characterize the molecular recognition between HIVp and dimer inhibitors.  
HDX can provide the first structural evidence defining the mechanism of HIVp 
dissociative inhibition by small molecules.  HDX could be broadly applicable for 
a range of active-site and allosteric inhibitors. 
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Chapter 1 
Introduction 
 
Structure Based Drug Design 
Structure-Based Drug Design (SBDD) began with the “Lock-and-Key” 
hypothesis of protein-ligand binding, proposed by Emil Fischer in 1890.1  Previous 
success depended on finding the correct “key”, often a small molecule drug mimicking a 
natural ligand, for a particular “lock”, the protein receptor surface.  Finding the right key 
can involve arduous experimental verification of a library of compounds against a target, 
and often includes a structure-based analysis of the screened small molecules.2  Although 
this empirical method reveals information about the properties of the small molecules 
tested against a protein target, the method does not provide any information about the 
protein binding pocket. 
The lock-and-key hypothesis is significant, albeit simplistic.  Fischer correctly 
recognized the importance of complementary shape between a ligand and the receptor 
pocket.  Fischer also correctly identified the principle understanding that the ligand and a 
protein pocket should share complementary chemical properties: 1) increase favorable, 
cooperative electrostatics while minimizing unfavorable interactions (i.e. two positively 
charged functional groups near each other), and 2) maintain the hydrogen-bonding 
network between ligand and receptor. X-ray crystallography, NMR spectroscopy and MD 
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simulations all provide a far more detailed understanding of a protein receptor.3-5  The 
information derived from a protein’s structure provides a three-dimensional chemical 
illustration of a protein’s surface, allowing the design of small molecules that 
complement the size and chemical properties of the binding site.6  The pharmacophore 
illustration of the protein surface can then be used to filter a small molecule library to 
identify a smaller set of ligands that allegedly match the receptor and can be 
experimentally tested against a protein.7  Several examples of early success in SBDD 
exist, such as dihydrofolate reductase and methotrexate, elastase with trifluoroacetyl-
dipeptide-anilide analogues, and the influenza virus neuraminidase with sialidase-derived 
inhibitors but are a few example systems.8-10 
 
Protein Flexibility 
Because we know that the protein and interacting small molecule ligands are not 
static as previously believed, as in the lock-and-key model, an induced-fit hypothesis 
proposes an explanation for protein-substrate systems.11  In the induced-fit hypothesis, a 
substrate can enter a protein’s active site and induce a protein conformational change, 
often enveloping the ligand.  Proteins in solution are naturally dynamic, with or without a 
ligand present.  A protein natively exists as an ensemble of protein conformations, 
resembling a probability distribution of states.12  At equilibrium, the population 
distribution of the conformational ensemble is distributed across several states, based 
upon how advantageous the free energy of one conformation compares to another.  The 
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population distribution of unbound protein conformations is skewed upon ligand or drug 
binding to favor the new energetically favorable bound state.13 
In this view of protein-ligand interactions, and given a diverse set of 
conformations, one can theoretically disrupt the normal population distribution of states 
by binding a ligand specifically tailored against a unique binding site of that state.14  The 
protein-ligand complex would then stabilize the conformation, resulting in a new 
distribution of conformation population states.  Regulation of enzyme activity through 
allostery will be discussed further in a later section, including regulation through protein-
protein interfaces.  
Protein motions are important in drug design.  Conformational changes occur 
upon ligand binding and can be monitored from the femtosecond time-scale for bonded 
atom vibrations up to seconds for subdomain interactions.15  Several methods can 
characterize a protein’s motions, from smaller, faster motions (i.e. methyl motions, loop 
motions, etc.) to larger domain motions and interactions.16  Ultrafast spectroscopic 
methods can provide detailed atomic vibrations on the femtosecond time-scale.  NMR 
relaxation techniques provide local dynamic information, from the picosecond timescale 
to the larger domain motions taking place over seconds.  X-ray crystallography, although 
static, provides the detailed atomic coordinates for computational simulations measuring 
protein motions in the femtosecond to microsecond range.  Hydrogen-deuterium 
exchange experiments coupled with mass spectrometry can provide information on the 
millisecond to second time-scale.  All of these techniques clarify protein motions to a 
system of interest. 
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Allostery 
The mechanistic basis of allostery is poorly understood, but it can be described by 
three different models.  The first model, the concerted MWC (proposed by Monod, 
Wyman and Changeux) model postulated that a conformation change, such as binding of 
a ligand by one enzyme subunit of a multimeric enzyme, will necessarily induce a 
conformational change to all other existing subunits.  The second model, the sequential 
KNF model (proposed by Linus Pauling and favored by Koshland, Nemethy and Filmer) 
states that the conformational change from one subunit, upon binding a ligand, is not 
necessarily propagated to all other subunits in a multimeric enzyme.17  The third model is 
an entropy-driven model, stating that entropy is the force for allosteric change.  
A classic case corresponding to the MWC model is the oxygen-transport protein 
hemoglobin.18  Hemoglobin (Hb) exists in a multi-subunit quaternary structure containing 
four heme groups with an coordinated iron in the center to bind oxygen for transport to 
the cells.  Hb has two distinct states: the R (relaxed) state and the T (taut) state.19  Upon 
binding of two oxygen molecules to the higher-affinity R state, the ligand induces a 
conformation change and Hb converts from the R to T state.20  At the T state, the two 
remaining available heme groups can bind additional oxygen molecules, but at a lower 
affinity towards the oxygen molecule. 
 In KNF model, the substrate binding event in one subunit increases affinity for 
ligands in adjacent subunits, similar to the MWC model; however, conformational 
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change in one subunit is independent of other subunits.21  Allostery generally involves the 
binding of a molecule, often called a modulator or effector molecule, on a protein surface 
that is not the active site but can regulate, either positively or negatively, an enzyme’s 
catalytic activity.  Binding of the effector molecule can be reversible, as in the case of 
aspartate carbamoyltransferase, but there are examples of non-reversible effector 
molecules covalently attaching to the protein surface.22  An example this can be observed 
in the covalent modification of phosphoryl groups to several residues, or by 
modifications to cysteine residues.23, 24 
Some have argued for the role of entropy as the driving force for allosteric 
changes.  Cooper and Dryden claim that every protein has a set of native motions and 
dynamics, including the frequency and amplitude of motions.25  Upon binding a ligand, 
the motions in the bound subunit are altered, causing a shift in the properties of motions 
in other subunits.  Popovych et al. demonstrated the first case of dynamically driven 
protein allostery characterizing the conformational states of the dimer CAP protein upon 
binding of cAMP  ligand to the CAP dimer.26  One model of allostery probably does not 
cover all examples of protein allostery; however, these three categories above can 
describe most known allosteric regulation mechanisms.   
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Figure 1.1: Example of Negative Allosteric Regulation.  From the unique protein 
conformation ensemble perspective, an enzyme’s catalytic activity can be regulated 
through an allosteric mechanism.  Binding an allosteric inhibitor to this unique 
conformational state negatively affects the affinity of the substrate to the enzyme active-
site. 
Our understanding of protein allostery has grown, allowing allostery to be 
engineered into a protein, as in the case of trypsin specificity.27  Although allostery was 
originally based upon observed conformational changes in symmetric proteins, such as 
hemoglobin or aspartate carbamoyltransferase, the term has been broadened to 
encompass any ligand binding event that affects another region’s ability to bind a ligand, 
positively or negatively, for either a multimeric or monomeric protein. Nussinov and 
colleagues have argued that every enzyme can be regulated in an allosteric fashion.28  
Since a protein exists as an ensemble of conformations, flexible protein, with its unique 
conformation ensemble, can be inhibited through ligand binding against a specific state, 
locking the protein into one conformation.29  Figure 1.1 above is an example of negative 
regulation of a protein’s catalytic activity.  An effector molecule, the allosteric inhibitor, 
binds within a region outside of the active-site and reduces substrate affinity to the active 
site. 
7 
 
 
Protein-Protein Interactions 
The human interactome has an estimated 650,000 protein-protein interactions 
(PPIs).30  The sheer size of the interactome indicates a favorable probability that a 
number of PPIs can be targeted with small molecules.  As an example, the Human 
Immunodeficiency Virus (HIV) exploits the use of host cellular proteins – often called 
HIV-dependent factors (HDFs) - to reproduce HIV particles.  Brass et al. screened a 
library of small interfering RNA (siRNA) to find candidate HDFs for possible drug 
targets.31  Brass identified 250 candidate PPIs involved in the life cycle of HIV as 
candidate targets for future drug design.  There are several examples of designed 
allosteric regulation of protein activity by targeted disruption of a protein-protein 
interaction.32-35  The p53-MDM2 PPI is a target of interest for cancer patients.36  The 
release of p53 (a protein that regulates the cell cycle in response to cellular stress leading 
to DNA damage) from MDM2 would aid in the restoration of p53 function in tumor 
suppression via apoptosis.  Maraviroc is FDA approved for treatment of HIV infections 
by blocking the HIV gp120 from binding to a host cell’s CCR5 receptor protein, a step 
needed for virus particle entry into the host CD4 expressing cells.37 
The average surface area for a protein-protein interaction is 1600 Å2, but can 
range up to 4000 Å2.38   That compares to range for an active site protein-ligand 
interaction at 300 to 1000 Å2.39, 40  The average weight for small molecules disrupting a 
protein-protein interaction is approximately 680 MW.  The higher molecular weight for 
PPI inhibitors is a concern with regards to Lipinski’s Rule of Five, a set of guidelines 
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describing the general physical properties of orally bioactive drugs.41  Lipinski’s Rule of 
Five states that for a drug to be orally bioactive, a drug must be 1) < 500 Da in molecular 
weight, 2) have ≤ 5 hydrogen -bond donors, 3) ≤ 10 hydrogen -bond acceptors, and 4) 
have a partition coefficient (or log P) < 5. There are exceptions to Lipinski’s Rule of 
Five, of course, as seen with Navitoclax.  Navitoclax, targeting the Bcl-XL--BAD PPI 
mediating apoptosis, breaks all but one of Lipinski’s rules and is currently in clinical 
trials.42, 43 
Ligand efficiency is a metric used to compare a ligand’s binding free energy 
relative to its size – defined specifically as the free energy of binding by the ligand 
(ΔGbound, kcal/mol units) over  the number of non-hydrogen atoms  – and can help 
indicate the druggability of a targeted region.44  Despite higher molecular weight, ligand 
efficiencies for ligands targeting PPIs remain comparable, albeit less, than the ligand 
efficiency of active site inhibitors, such as protein-kinase inhibitors or protease 
inhibitors.33, 34  The ligand efficiencies for PPIs can be explained by the observation, that 
PPIs regularly contain relatively small patches on the protein surface responsible for high 
affinity binding, commonly referred to as protein “hot spots”.45   
  Whether designing a small molecule to target a protein’s active site or an 
allosteric regulatory site to perturb an enzyme’s kinetics, SBDD is an iterative process of 
analysis, design, synthesis and experimental verification that leads to an optimized 
relationship between a protein surface receptor and its complementary, unnatural ligand.  
There are a growing number of computational techniques being developed to speed the 
cycle of SBDD and to expedite the process to bring new drugs to market. 
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Molecular Docking 
Molecular docking programs, which are computational programs that allow broad 
ease of access for common users and the most generally used, simulate protein-ligand 
interaction.  There are several docking programs available, such as DOCK, 
AUTODOCK, GOLD, GLIDE, FLEXX among others.46-51  The programs use varying 
parameters to search for the best fit between the receptor and the ligand.  Parameters can 
include complementarity of physical interactions, such as the shape between the receptor 
and ligand with regards to the Van der Waals (VDW) radius and atomic charge, and 
intermolecular interactions such as hydrogen bonds or hydrophobicity.52  The ligand 
poses generated from molecular docking simulations are then scored based on the 
parameters, ranking a predictive pose’s affinity between a receptor and ligand.  Receptor 
flexibility has been increasingly incorporated to help integrate motions occurring in 
ligand-binding events. 
 
Molecular Mechanics 
Molecular mechanics (MM) is the simulation of molecular system using classical 
Newtonian mechanics.  Quantum mechanics (QM) is more accurate than MM and may 
also be employed; however, QM comes a penalty, as computational hours rapidly grow 
proportional to the number of atom simulations, thus limiting the number of atoms which 
may be simulated to computational resources.53  The atom limit on QM simulations 
designates Newtonian mechanics as better suited for larger molecular systems, such as a 
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solvated protein.  There are a number of MM programs including Chemistry at HAvard 
Molecular Mechanics (CHARMM), Assisted Model Building with Energy Refinement 
(AMBER), GROningen MOlecular Simulation (GROMOS), and Not (just) Another 
Molecular Dynamics (NAMD) program.54-57 
Force-field parameters were developed to approximate the Newtonian mechanics 
the atomic forces experience within a molecular system.  The energy within a system is 
typically calculated as the summation of several atomic forces: 1) bonded atomic forces, 
such as bonded atom vibrations; 2) bonded angles amongst atoms and dihedrals; and 3) 
non-bonded forces, such as electrostatic and VDW terms.  The current AMBER force 
field is shown in the following equation:58  
𝑉(𝑟) =  � 𝐾𝑏(𝑏 − 𝑏𝑜)2
𝑏𝑜𝑛𝑑𝑠
 +  � 𝐾𝜃(𝜃 − 𝜃𝑜)2
𝑎𝑛𝑔𝑙𝑒𝑠+ � (𝑉𝑛 2⁄ )(1 + 𝑐𝑜𝑠[𝑛𝜙 − 𝛿])
𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙𝑠
 
+ � ��𝐴𝑖𝑗 𝑟𝑖𝑗12⁄ � − �𝐵𝑖𝑗 𝑟𝑖𝑗6⁄ � + �𝑞𝑖𝑞𝑗 𝜀𝑟𝑖𝑗⁄ ��
𝑛𝑜𝑛𝑏𝑖𝑗
 
In AMBER’s force field implementation, the first three summation terms are the bonded 
terms.  Bond stretching is noted in the first term, where Kb is the stretch constant between 
two atoms, and b and bo are the bond length and equilibrium bond length at equilibrium, 
respectively.  Angles are shown in the second term, Kθ is the angle constant, and θ and θo 
are the bonded angle and the bonded angle at equilibrium.  Dihedrals are summed in the 
next term, here Vn is the dihedral constant, and ϕ and δ are the dihedral and the dihedral 
phase angle, respectively.  The non-bonded terms, representing the VDW modeled with a 
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12-6 Lennard-Jones potential and the charge-charge interactions are each calculated as 
point-charge interactions.  The 12-6 Lennard-Jones potential accounts for both the short 
range repulsive interactions.  The Pauli repulsion, indicated by the r (-12) term, describes 
favorable or unfavorable ionic interactions.  The attractive long range terms, such as 
VDW, are accounted in the r (-6) term.  Interactions between two point charges (qi and qj) 
are calculated as a Coulombic potential so that rij is the radius between the two point 
charges and ε is the dielectric influence. 
 Force-field testing optimizes MM calculations, reflecting empirical 
measurements.  In 1995, Cornell et al. published the AMBER94 Force Field serves as the 
basis for AMBER simulations for over a decade.59  There have been several iterations of 
the AMBER94 Force Field, including refinement of parameters (such as AMBER99 
Stony Brook, or AMBER99SB), additions in the force field to include for fluctuations in 
polarizability within residues, force field parameters for sugar molecules, or to include 
Generalized AMBER Force Field (GAFF) parameters for small molecules.60-64  
 
Molecular Dynamics 
 Molecular Dynamics (MD) is a technique combining the MM force fields and 
Newton’s Second Law, 𝐹 =  𝑚 ∗ 𝑎, to study large biomolecular systems along the 
course of a trajectory.  The trajectory length relies on available computational resources 
and the size of the biomolecular system; it resembles QM in this regard, although with 
less of a penalty. Efforts have been made to parallelize and accelerate the calculation to 
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allow trajectories into the microsecond range.  For our studies, the AMBER package was 
chosen as the MM software package. 
 Although there is not one general, explicit method, there are general principles 
and protocols ubiquitous to system setups.  Coordinates for initial atom position are 
typically provided from experimental X-ray or NMR sources.  Parameters for atoms are 
then assigned dependent upon force field (AMBER99SB for our studies), and atom initial 
velocities are assigned by a Maxwellian distribution determined from the user defined 
seed number.  Typically, MD equilibration is a series of steps intended to relax the 
biomolecular system and, depending on size of system, can last into the production 
portion of an MD trajectory.  Proper equilibration of a system has been proven important 
to a system, as equilibration overcomes secondary effects of crystallization (i.e. crystal 
packing effect causes improper bond distances or dihedral).  Crystal packing effects are 
particularly troublesome, as they may result in an unconventional structural pose or bias 
the protein conformational ensemble towards one state over a more energetically 
favorable conformation.65  Water molecules are added to a system explicitly in MD 
simulations in a crystalline form and must be equilibrated to ensure complete solvent 
contact along the solvent accessible surface area (SASA) of the biomolecular system.66  
TIP3P and TIP4P are common parameters used for waters and are treated as a rigid 
molecule to simplify the calculation.67, 68  
 After equilibration, the MD trajectory continues into the production phase (also 
simply referred to as the “trajectory”) of the study.  Structural and energetic information, 
such as atom coordinates, velocities, energies and temperature, can be outputted from the 
trajectory at user-specified intervals.  Analysis of the trajectory is guided by the 
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information the user seeks.  Program packages, similar to the Multiscale Modeling Tools 
for Structural Biology (MMTSB) and AMBER’s ptraj analysis program, are available to 
assist in data analysis.55, 69  One common analysis, a root mean square difference 
(RMSD), can be used to quantitatively measure protein fluctuations compared to a 
reference frame, often the start of the production run or an averaged position within a 
portion of the trajectory.  Pertinent to studies of protein-ligand interactions, a ligand’s 
contact information onto a protein surface can be deduced from the MMTSB’s contact 
script.  The MMTSB contact script defines a “contact” as the minimum inter-residue 
distance between every heavy atom pair less than 4.2 Å.  The Dictionary of Secondary 
Structure Program (DSSP) assigns secondary structure (i.e. β-sheet, α-helix) on a per 
residue basis depending on the geometric similarities of the residue’s hydrogen-bonding 
network to known secondary structures.70   Normal Mode Analysis, Correlated 
Dynamics, bond angles (i.e. phi- / psi-angles for Ramachandran Plots) can all be derived 
from MD trajectories based upon the information needs of the user. 
 
Implicit Solvation 
 Implicit solvation is a sampling technique used to reduce the number of atoms in a 
system, and therefore reduce the computational demand for its model.  An implicit 
solvation simulation models the solvent as a continuous medium used to approximate the 
solvent’s mean free energy influence in a solute-solvent system as calculated by the 
Poisson-Boltzmann (PB) equation, instead of modeling the solvent explicitly with 
individual water molecules.71  The generalized Born (GB) is an approximation of PB 
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making GB more generally applicable due to its computational efficiency.72  Although 
the medium is continuous, its properties can be changed (i.e. the dielectric within a lipid 
bilayer).  Implicit solvation is considered a sampling technique, since the system of 
interest can sample more protein conformational ensembles than a standard, explicit 
solvent MD trajectory can produce within an equivalent amount of computational 
effort.73  Since this is an approximation of the solvent’s free energy, extensive testing of 
the continuous medium must be performed.  For our studies, GB(II)SA-OBC was the 
preferred solvent parameter.74, 75 
 Langevin Dynamics (LD) simulations are simulations, often implicitly solvated 
but which can be explicit, with the Langevin equation specifically applied.  The Langevin 
equation is: 
𝑀?̈? =  −𝛻𝑈(𝑋) −  𝛾𝑀?̇? + �2𝛾𝑘𝑏𝑇𝑀𝑅(𝑡) 
Here, U(X) is the potential of an atom interacting with the solvent medium.  ∇ is the 
gradient of the potential giving -∇U(X) the force of the potential.  ?̇? and ?̈? are the first 
and second derivatives, respectively, of atoms at a given position X at a time-point in the 
trajectory (Xt); these give the velocity and acceleration of those atoms, for each.  M is the 
mass of the atom, kb is the Boltzmann constant, T is temperature and R(t) is the Gaussian 
Process.  The Langevin equation can be applied to hold the temperature of a system 
constant, but for implicit solvation, the benefit of the Langevin equation is given in γ, a 
damping constant.  The damping constant gives the continuous medium a viscosity term, 
so the atoms will “collide” similar to a solvated environment and not in a gas-phase 
environment.   
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Monte Carlo Method 
 The Metropolis Monte Carlo (MC) method for molecular mechanics is a sampling 
method based upon the Monte Carlo algorithm that relies on a stochastic approach to 
produce its designed result.76  For MD, the designed result is the movement of atoms.  
Although it is a force field-based method similar to MD, the MC method transposes a 
small number of atoms in a time-step, unlike single atom displacements in MD, to a new 
state (or geometric position).  MC then calculates the potential energy at the new state.  
The decision to accept, or reject, the new state is decided upon a Boltzmann distribution 
of the potential energy from the new position and is compared against a randomly 
generated number in the range of 0 to 1.   
MC is a markov chain process; wherein exists a finite number of states and 
transitions from one state (i) to the next (i+1) is not influenced by the previous (i) state.  
The MC method is an iteration of several steps: 1) specify initial atom coordinates, 2) 
transpose by random displacement, 3) calculate differences in potential energy, 4) 
determine if the change in potential energy is less than 0, then go to step 2, otherwise 5) if 
the Boltzmann distribution of the potential energy is less than a randomly generated 
number, the new coordinates are accepted and proceeds back to step 2 (if greater or equal 
to the randomly generated number, original coordinates are retained and proceeds to step 
2).  The number of MC iterations is user defined. 
The Biochemical and Organic Simulation System (BOSS) is a package of MM 
force field based programs including the MC method.77  The OPLS (Optimized Potentials 
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for Liquid Simulations) parameters are used to simulate common solvents.78  The 
potential energy formula is similar to that of AMBER.  The BOSS program package is 
used by our laboratory to minimize solvent molecules along a protein surface. 
 
Protein Surface Mapping 
 One technique to map the chemical surface of a protein for SBDD is to saturate 
crystallized proteins in a chemical fragment solvent prior to X-ray crystallography.79  The 
crystal soaking technique has a fairly high throughput capacity and has a high resolution 
to spatially differentiate the chemical properties along a protein surface.80  In crystal 
soaking, a previously crystallized protein in a unbound (apo) state is saturated in a series 
of solutions composed of a chemical fragment that represents a physical steric constraint 
(i.e. aromatic), or a physiochemical property of interest (i.e. hydrophobicity, hydrogen-
bonding).  The chemical fragments affix themselves in regions along the protein surface 
that are energetically and conformationally favorable to the fragment’s chemical 
property.  The fragment map of the protein surface can then be used to build ligands with 
features comparable to the targeted receptor.  Chemical fragment crystal soaking has 
been used for numerous targets; however, crystal soaking has its own disadvantages.  
Crystals are often sensitive to the solvents of interest, which leads to poor diffraction 
patterns.  In addition to the sensitivity of the crystal lattice to the chosen solvent, the 
crystal soaked map of the protein surface still only offers a static picture of the protein 
and is not representative of the protein motions.  Lastly, electron density on protein 
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surface is ambiguous and can be indeterminate whether the density is for water or a 
chemical fragment. 
There are computational techniques that mimic the crystallographic soaking 
method, such as the Multiple Copy Simultaneous Search (MCSS) method developed by 
Karplus.81  This method places multiple copies (on the magnitude of hundreds to 
thousands) of a chemical fragment near the targeted protein region.  Each fragment is 
permitted to interact with the protein surface, but not with other fragments.  The fragment 
probes are then minimized to the protein surface, converging to positions both 
energetically and conformationally favorable for the chemical fragment.  The protein 
itself is represented by either a static structure or a small degree of dynamic information 
can be illustrated using a restrained MD simulation.  The MCSS method can result in too 
many energy minima positions, in which case arbitrary energetic cut-offs are often used 
to filter the minimized probes, to retain the more energetically favorable probes.82 
 
Multiple Protein Structures 
 The multiple protein structures (MPS) method is an evolution of the 
MCSS method to computationally map protein surfaces, but MPS was conceptualized to 
incorporate greater conformational sampling of the flexible protein target.  A study by 
Carlson et al. pioneered the MPS method against the apo Human Immunodeficiency 
Virus type 1 (HIV-1) integrase protein.83  The method was refined by Meagher, et al. and 
made robust over several protein systems.84   
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The first step of MPS includes mapping several protein conformations’ with 
chemical fragments.  Several chemical probes are individually mapped to each static 
structure.  Methanol, ethane, and benzene fragments flood the target region and represent 
hydrogen-bonding, hydrophobic and aromatic interactions, respectively.  The probes are 
minimized to the protein surface by the Multi-Unit Simulation of Interacting Chemicals 
(MUSIC) program, which is part of the BOSS programming package.  MUSIC performs 
a low-temperature MC minimization that allows the probes to search for energetically 
favorable geometric positions along the protein surface. The mapped conformational 
structures can be derived from several sources: NMR, MD or X-ray crystallography.  
Although one could use any initial atomic coordinate source, NMR has demonstrably 
providing the most conformational sampling, followed by MD, and then crystallographic 
sources.85  
After probe minimization along the protein surface, clusters of probes are 
observed.  A single probe, the lowest energy minimum within the cluster, is used to 
represent the cluster (called a parent probe).  Each protein structure, with minimized 
parent probes, is then overlaid to a single structure.  Protein structure alignment produces 
new clusters of parent probes.  The clustered parent probes are then compared across the 
multiple conformations to identify chemical and spatial consensus across multiple 
conformations.  The consensus cluster defines characteristics of the pharmacophore 
model and represents the average position and RMSD of the clustered parent probes.   
The MPS pharmacophore model represents the chemical and spatial 
complementary a small molecule must have to bind against the protein pocket.  The 
pharmacophore can filter, in silico, a library of small molecule conformations based upon 
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the properties of the pharmacophore model.  MPS provides enrichment in successful hits 
superior to experimental chemical library screening methods.  The MPS technique has 
demonstrated experimental success for filtering small molecules able to inhibit its 
intended target.  Refinement of the MPS method was required to create a robust method 
over several protein systems.   
The MPS method was validated through demonstration, selectively discriminating 
small molecule inhibitors of HIV-1 protease (HIVp), dihydrofolate reductase (DHFR) 
and murine double mutant (MDM2).86-88  In the case of DHFR, the MPS method 
selectively filtered species-specific inhibitors, discriminating high-affinity DHFR 
inhibitors over more general, lower-affinity inhibitors.  Incorporating longer DHFR MD 
trajectories, and therefore more conformational sampling, produced better-performing 
pharmacophore models, which alludes to the importance of protein flexibility in SBDD.  
The MPS technique identified five novel small molecules, providing new diverse 
chemical scaffolds, targeting the p53-MDM2 protein-protein interaction.  The MPS 
procedure was also performed to target the allosteric “eye” site on HIVp.89 
 
HIV-1 Protease as a Drug Target 
Human Immunodeficiency Virus (HIV) was first diagnosed in the United States 
in 1981, and today, we have a cocktail of drugs – known as Highly Active Antiretroviral 
Therapy, or HAART – that target four HIV protein targets: protease, integrase, reverse 
transcriptase, and the gp120-CD4 protein-protein interaction.90  These four targets are 
necessary for the maturation and propagation of the active HIV particle.  Genomic viral 
replication has a low fidelity rate, creating a high error rate in viral replication; whereas 
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mutant HIV proteins allow the variants to escape drug efficacy.  The effect of mutations 
is reflected in high rates of drug resistance to nearly 20% of marketed HIV inhibitors, and 
a drug-resistant HIV transmission rate near 9%.91  The 2008 UNAIDS reports an 
approximate 33 million HIV infected patients, resulting in 2 million deaths and a number 
of individuals harboring HIV.  Therefore, a strong need for development of new 
therapeutics to attack HIV in a novel fashion is crucial.92 
The HIV genome is stored on a single double stranded RNA and is split into three 
major polyproteins: the Gag, Pol and Env polyproteins.  The Gag and Env polyproteins 
primarily encode structural proteins necessary for the viral particle.  The Gag polyprotein 
splits into four major domains that contain critical viral proteins: the matrix, capsid, 
nucleocapsid, and the p6 protein.93   The matrix domain contains the Gag protein, when 
myristoylated, binds to the host cell membrane.94, 95  The myristoylated, membrane-
bound Gag protein then creates neighboring Gag-Gag protein-protein interactions.  These 
PPIs create the viral particle budding.  The Env glycoproteins, such as gp120 and gp41, 
are recruited to the matrix to provide the budding viral particle its envelope proteins. 96  
The Gag nucleocapsid domain contains proteins that bind to replicated double-stranded 
viral RNA, which anchors the RNA to the viral matrix.  The capsid provides an inner 
compartment for viral proteins (protease, integrase, and reverse transcriptase) necessary 
for function.  Along with six other accessory proteins, such as Nef and Vif, which have 
roles at different stages of viral replication, the HIV particle can be reduced to a 
molecular entity of 15 total proteins and RNA.97 
 Upon release from the cell, the immature HIV particle is proteolyzed by HIV 
protease (HIVp) in a series of events, transforming it into an infectious viral particle.98  
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This series of proteolytic events is critical to the HIV life cycle, making regulation of 
HIVp catalysis a viable therapeutic target.  Down regulation of HIVp catalysis is 
achieved by preventing the natural substrate from entering the active site.  This is the 
traditional method to regulate HIVp activity, thereby halting HIV particle maturation.99, 
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Competitive Inhibitors of HIV-1 Protease 
The first HIVp structure was characterized by Navia and colleagues, deposited in 
the Protein Data Bank (PDB) with the identification (ID) of 2HVP.101  HIVp is a 
homodimer with C2-symmtry, 99 amino acids, and shares a similar fold to other 
characterized apartyl proteases.102  As of publication of this dissertation, there are 
hundreds of structures in the PDB of unbound HIVp, ligands complexed with HIVp, 
mutant variants of HIVp, and combinations of these categories.  The repository includes a 
tethered form of HIVp with several Gly residues connecting the two monomer units 
through the N- and C-termini.103  PDB 4HVP is the first structure to characterize the 
relationship between HIVp bound to an inhibitor, which blocks the HIVp active site from 
substrate catalysis.  Since 4HVP publication, 10 different drugs are U.S. Food and Drug 
Administration (FDA) approved and released to market to target the inhibition of the 
HIVp proteolysis via direct competition of the active site over its natural peptide 
substrate.104 
 HIVp performs proteolytic cleavage along the amino acid backbone through a 
general acid (GA)/ general base (GB) reaction involving two catalytic Asp25 (and 
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Asp25’) residues and a shared water molecule, “cutting” the peptide substrate into two.  
The reaction mechanism empirically described by Bihani and colleagues uses 
crystallographic techniques to trap two short peptides complexed with HIVp after 
cleavage.105, 106  PDB ID 3DOX describes the role of the water molecule in the GA/GB 
reaction between the HIVp catalytic Asp residues and the cleaved substrate.  Although 
this is the first empirical evidence of the GA/GB reaction, Hosur and colleagues were not 
the first to propose the GA/GB mechanism.  Several groups proposed a GA/GB 
mechanism in lieu of a direct nucleophilic catalytic mechanism, applying computational 
methods to argue the GA/GB reaction is more energetically favorable over the direct 
nucleophilic mechanism.107, 108  The cyrstallographic snapshot provided in 3DOX is 
conclusive empirical evidence of the GA/GB reaction mechanism for HIVp proteolysis. 
 Currently, the 10 drugs on the market that target the active site of HIVp inhibit 
catalysis through direct competition by mimicking the natural substrate.  With the 
exception of Tipranavir, all HIVp drugs are peptidomimetic derivatives of the natural 
substrate.  Peptidomimetics have poor pharmacokinetic properties and toxic side-
effects.109  In addition, all 10 of the HIVp drugs are susceptible to degradation by 
cytochrome P450 enzymes, particularly CYP3A4.110  Often, Retinovir is coadministered 
with another HIVp inhibitors to reduce metabolism, but coadministration of two 
peptidomimetics exacerbates the toxicity and side effects to maintain a high drug 
concentration, preventing HIVp catalysis.111  Marinec et al. improved the 
pharmacokinetic properties of HIVp drugs by covalently attaching the natural ligand 
FK506-binding protein (FKBP) to Amprenavir, an FDA approved HIVp drug.112  
Bifunctionalizing Amprenavir with FK506 permitted greater partitioning of the 
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bifunctional drug into the cell and reduces drug metabolism.  Improvements to the 
pharmacokinetic properties of HIVp drugs allow lower dosing, thereby reducing side 
effects of HIVp drugs. 
HIVp escapes drug efficacy through selective pressure caused by the active site 
inhibitor, evolving the protease.  Mutations in HIVp frequently lie outside the active site 
and do not interact with it, nor do they affect ligand binding directly.  The mutations are 
often conservative mutations, so that a mutation at a single specific residue will not 
significantly alter the chemical properties of that residue (i.e., Ile15Val).  Conservative 
mutation(s) results within the HIVp core a phenomenon termed “hydrophobic sliding,” 
described by Celia Schiffer.113  A small hydrophobic residue within the core mutates to 
another small hydrophobic residue, so as not to generate steric clashes between residues 
within the core.  A steric clash within the HIVp core would physically constrain the core 
to transition between the different states (i.e., open to closed).  Although mutations do not 
directly affect ligand binding, they do alter the shape of the receptor pocket as the 
protease transitions from one state to another, indirectly affecting the complementary 
between the ligand and receptor. 
First-generation of HIVp inhibitors, such as Saquinavir, Ritonavir and Indinavir, 
were designed with strong entropic consideration to the HIVp active site, even at the 
expense of unfavorable enthalpic interactions.  Second-generation HIVp inhibitors, such 
as Lopinavir, Atazanavir and Darunavir, posses comparable, or slightly less favorable, 
entropic interactions, but a stronger emphasis on increased enthalpic interactions when 
bound to HIVp.  The different binding mechanisms between the two generations were 
investigated by Freire and colleagues using Isothermal Titration Calorimetry (ITC).  The 
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second-generation inhibitors increased the enthalpic contribution by creating a hydrogen-
bonding network with the peptide backbone, as opposed to hydrogen-bonding to amino 
acid side chains.  KNI-764, a second-generation inhibitor precursor, revealed another 
important compound feature, which is that it must be flexible at crucial positions to 
account for new motions that occur due to mutations.  Although the compounds KNI-764 
and KNI-262 are chemically similar and have comparable binding affinities against the 
wild-type HIVp, the affinity of KNI-262 reduces against the mutant V82F/I84V HIVp 
mutant due to unfavorable flexibility within the compound.  Freire emphasizes that for 
certain targets, such as wild-type HIVp and variants, it is important for the compound to 
be adaptively flexible to account for new receptor pocket motions caused by mutants. 
 
Allosteric Regulation of HIV-1 Protease 
Overcoming the loss of drug efficacy caused by mutant strains of HIVp is a 
desirable goal in the development of future therapeutics.  Researchers are searching for 
and manipulating allosteric regions in HIVp to inhibit multi-drug resistant strains of 
HIVp.  Perryman et al. used molecular constraints in MD simulations and HIVp as an 
example of allosteric control.114  Perryman began with a bound, closed HIVp structure for 
both the wild-type and mutant HIVp (PDB 1KZK and 1D4S, respectively) and then 
deleted the enclosed KNI-764 ligand in both structures.  Perryman continued to place a 
distance (7.7 and 10.5 Å) force restraint on the alpha-carbon atoms between residues 
Gly40 and Gln61 of HIVp; prior to performing MD simulations.  In the restrained MD 
simulations, Perryman observed that the flaps never transitioned to the open 
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conformation.  In the larger distant restraint (10.5 Å), the flaps failed to return to the 
semi-open conformation despite lacking a bound ligand to stabilize the closed state.  The 
restrainted simulations suggested a means of allosteric control of flap dynamics by 
restraining the cheeks through the “allosteric groove” between residues Gly40 and Gln61.   
 
Figure 1.2: HIV-1 protease topology.  HIVp is a 99 amino acid homodimer with C2 
symmetry.  Common names for regions in the HIVp are indicated as defined by 
Perryman, et al.  Black spheres indicate the alpha-carbons for Gly40 and Gln61, which 
distance restraints were placed for MD simulations.  Asterisks (*) describe the location of 
the allosteric groove between Gly40 and Gln61.  The dashed box indicates the dimer 
interface of HIVp, defined as the region bordered by the two α-helices, the β-sheet, and 
the backbone of the active-site.  The two catalytic aspartic acids are shown as sticks, 
image generated via PyMol. 
The X-ray crystallographic structure PDB 1TW7 demonstrated an empirical 
representation of putative allosteric control via the allosteric groove Perryman described.  
1TW7 showed the HIVp flaps in a novel conformation, terming the conformation as 
“wide-open” due to the novel and skewed position of the flaps.115  Layten et al. deleted 
the wedged flap tip and performed MD simulations of the skewed conformation of 
1TW7.116  Their simulations demonstrate that 1TW7 quickly reverts to a semi-open 
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conformation without the wedge flap tip; whereas the skewed 1TW7 is stabilized by the 
crystal packing effect.  Although Layten’s simulations show 1TW7 was stabilized by 
crystal packing effects, they do not necessarily prove that the flap tip can bind in the 
allosteric groove.  Studies by Lexa, et al., showed a peptidomimetic based upon the 
wedged flap tip residues could not maintain contact over the course of their MD 
simulations, and therefore suggesting that flap tip stability to the allosteric groove is 
unfavorable.117 
Other regions outside the HIVp allosteric groove are of interest to researchers, in 
their efforts to prevent HIVp proteolytic turnover.  In 2008, Damm et al. utilized the MPS 
method to discover a small molecule with properties that match the mapped 
complementary space of the eye site, and the small molecule was determined to inhibit 
HIVp catalysis.89  Damm performed MD simulations of the eye small molecule 
complexed to HIVp to demonstrate the mechanism of protein-ligand binding; however, 
there is no current structural evidence confirming the ligand’s binding mechanism.  
Although there is no structural evidence of Damm’s bound eye site ligand, a growing 
amount of corroborating evidence supports the site’s ability to bind a ligand.   
Concurrent with Damm, Böttcher et al. co-crystallized a bound HIVp with a 
pyrrolidine-derived inhibitor (PDB 3BC4).118  Unique to 3BC4, the ligand stabilizes the 
open HIVp conformation by positioning the naphthyl rings moieties of the ligand 
underneath the flap near the eye site.  PDB 3BC4 crystallized the pyrrolidine ligand 
bound in two conformations (α and β).  The authors speculate the β conformation is an 
artifact of crystallization, stabilized by neighboring crystal contacts.  Lexa and Carlson 
performed MD simulations of HIVp bound with the ligand in an α, β and α + β 
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conformation.119  Their simulations demonstrated that the α ligand conformation of 3BC4 
is the most stable of the three.  The simulations reported a ligand conformational change 
in the trajectory.  While one of the ligand’s naphthyl ring stayed bound to the eye site, the 
other naphthyl ring flips position to bind into the S1/S1’ or to the S2/S2’ pocket.   
The favorability of this pyrrolidine derivative conformation, with one naphthyl 
ring in the eye site and the other in the active-site pocket, corroborates EPR studies of the 
HIVp performed by Torbeev et al.  Torbeev measured the distance between the MTSL 
spin-labeled residues at position 55 and 55’, and compared the distance to the equivalent 
residue positions in MD simulations.120  The result of Torbeev’s EPR work reported 
HIVp is asymmetric when bound by the three traditional inhibitors (MVT-101, KVS-1, 
JG-365).  The HIVp inter-residue distance supports a “semi-open/closed” flap 
conformation, unlike the “closed/closed” flap conformations seen in bound HIVp crystal 
structures.  The asymmetric “semi-open/closed” flap conformation would allow the eye 
site to exist, asymmetrically, in a ligand-bound HIVp.  Perryman et al. soaked crystal of 
HIVp with several chemical fragments. 121  One of the fragments minimized to HIVp, a 
5-nitroindole fragment, was found to be stably bound at the eye site corroborating the 
existence of the allosteric site.  The fragment was bound to only one monomer of the 
symmetric HIVp dimer.  Asymmetric binding by the chemical fragment further supports 
the asymmetric binding requirement for this mode of inhibition. 
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HIV-1 Protease Dimer Interface  
HIVp monomers must dimerize to allow catalytic activity, which distinguishes it 
from other aspartic proteases.  Because HIVp is an obligatory dimer, and due to the 
highly conserved nature of the dimer interface, the dimer interface becomes a highly 
attractive target to prevent formation of the active catalytic site.  The dimer region of 
HIVp is approximately 1800 Å2 in Solvent Accessible Surface Area (SASA), about 1000 
Å2 larger than an average SASA dimer interface for homodimeric proteins.122  75% of the 
Gibbs free energy resulting from dimerization of the HIVp monomers lies within the β-
sheet region.123  The interdigitating β-sheet region accounts for 50% of the SASA dimer 
interface contacts.124  Mature HIVp is an extremely stable dimer. ITC experiments by 
Todd et al. measured  a dissociation rate constant, Kd, (sub nanomolar) at equilibrium at 
123 pH 5.  Xie and colleagues performed sedimentation equilibrium studies of the HIVp 
dimer at neutral pH.125  At a more physiological pH, Xie reported a Kd three orders of 
magnitude higher (5.8 µM) for the pseudo-wild-type, autolysis-resistant HIVp mutant 
(Q7K/L33I/L63I) in their studies.  
 
Dimer Interface Inhibitors 
Zhang et al. performed one of the earliest examples of dissociative inhibition of 
HIVp.126  By creating a peptidomimetic based on the last four residues of the C-terminus, 
Zhang showed through kinetic analysis and sedimentation equilibrium experiments that 
the peptidomimetic C-terminus can inhibit HIVp activity via a dissociative mechanism.  
Their kinetic analysis, termed the Zhang-Poorman assay, is a fluorescent-based kinetic 
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analysis that distinguishes dissociative inhibitors from competitive.  The Zhang-Poorman 
assay is now commonly performed by other investigators to determine the inhibition 
mechanism and rate for dissociative inhibitors.  The assay corroborates other biophysical 
techniques (sedimentation equilibrium, liquid chromatography/mass spectroscopy) to 
characterize the dissociative mechanism of HIVp inhibition.127 
Currently there are two major strategies (monovalent and bivalent) to construct 
ligands against the dimer interface; however, both strategies are rooted in principle by 
mimicking short sequences of the N- and C-terminal peptides.128  Althought the N- and 
C-termini can inhibit HIVp, monovalent inhibitors are derived from the C-terminus due 
to its position between the monomer’s termini.  Bivalent peptidomimetic inhibitors 
contain fragments that complement the N- and C-termini sequences with a linking region 
that connects the two peptide chains.   
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Figure 1.3:  Design of Dissociative Inhibitors.  One HIVp monomer molecular surface 
is shown while symmetric residues 1-5 and 95-99 are represented in ball and sticks.  
Current generation of HIVp dissociative inhibitors are designed to mimic the residues 
naturally compromising the dimer interface. 
Schramm and colleagues targeted the dimer region using short peptidomimetics 
derived primarily from the C-terminus.128  Schramm continued the development of his C-
terminal derived monovalent peptidomimetic inhibitors by determining the core sequence 
necessary for dissociative inhibition and added a palymitic acid chain to the N-terminus 
of the inhibitor.129, 130  Bannwarth et al. varied the length of the carbon chain in the 
palymitic acid in Schramm’s lipoprotein moiety.131  They also demonstrated that dimer 
inhibitor efficacy was comparable against mutant strains of HIVp, unlike other 
competitive site inhibitors.  Caflisch et al. theoretically mapped the dimer interface using 
the MCSS method.132  The MCSS map of the HIVp monomer determined that the 
complementary Phe99 position is large and can accommodate a variety of groups.  The 
addition of a thyroxine group to Schramm’s peptidomimetic corresponding to the 
complementary Phe99 position increased potency of the monovalent compound, and 
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validated Caflisch’s MCSS dimer interface map.133  Breccia et al. synthesized a 
monovalent series based on Schramm’s compounds, including a positively charged 
guanidinium group onto the N-terminus of peptidomimetic.134  Breccia intended for the 
positively charged guanidinium group to interact favorably with the negatively charged 
C-terminus.   
Jean Chmielewski pioneered the development of bivalent peptidomimetics 
targeting the HIVp dimer region, linking the N- and C-termini with an alkyl chain of 
carbons.135  She optimized the length and flexibility of the alkyl linker region, 
determining an effective linker length of 16 carbons.136  The ligand size was reduced to a 
core peptidomimetic sequence necessary to prevent dimerization, and has increased the 
strength of bivalent compounds.137-139  Bouras et al. recognized the unfavorable entropy 
penalty associated with a flexible linker and constructed a bivalent series with more 
constricted linkers.140  Bouras substituted Chmielewski’s 16-carbon alkyl chain with 
several aromatic groups (resorcinol, pyridinediol and naphthalenediol) to create a series 
of bivalent molecules called “molecular tongs”.  Derivatives of the molecular tongs 
include substitutions to the aromatic group to increase favorable interactions and the 
insertion of chemical fragments to replace the peptidomimetic amino acids.141, 142 
Currently, a large body of empirical evidence indicates dissociative inhibition by 
dimer inhibitors.  Dimer inhibition is largely ascertained by means of Zhang-Poorman 
kinetic analysis.  Unfortunately, the fundamental relationship between the dimer 
inhibitors and the HIVp dimer interface is not understood.  Frutos et al. performed 2D 
[1H-X]-HSQC NMR using a labeled [2-13C]-Trp incorporated into the pseudo-wild-type 
HIVp.143  Trp was labeled primarily because there are only two residues (Trp6 and 
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Trp42), with one (Trp6) in the dimer interface.  Frutos reported chemical shifts at the 
Trp6 residue, which suggested ligand binding near the residue.  The authors then 
performed docking simulations, using AutoDock3.  Frutos centered the grid between 
residues 96-99 of monomeric HIVp, and performed molecular docking to simulate the 
receptor-ligand binding mechanism.  Their study indicates inhibitor binding near Trp6; 
however, by selecting a grid center on the C-terminus of the monomeric HIVp, the 
authors restricted their docking simulations to the area occupied by the complementary 
C-terminus, which biased their result. 
The greatest challenge in designing better, non-peptidomimetic inhibitors to target 
the HIVp dimer interface is the lack of structural information.  Greater structural 
information would clarify the relationship between the HIVp dimer interface and 
dissociative ligands bound, presumably, at the dimer interface.  This recalls the problem 
associated with the lock-and-key hypothesis; we currently have many keys, but little 
understanding behind the relationship between the lock and the key.   
The studies presented in this dissertation will attempt to elucidate this 
fundamental relationship.  The proceeding chapter details the use of the MPS procedure 
to map the dimer interface of HIVp, creating a pharmacophore to filter a small molecule 
library matching the complementary space.  The chemical map of the complementary 
space filtered, in vitro, a three dimensional library of small molecule inhibitors able to 
selectively inhibit HIVp in an allosteric region via the dimer interface.  Chapter three 
describes an attempt to computationally model the putative binding mechanism between 
current dissociative inhibitors complexed to the dimer interface.  Although these models 
do not converge to a consensus binding mechanism, they do report the hypothesized 
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binding mechanism is unfavorable and is likely not the binding mechanism.  Chapter four 
explains an effort to characterize critical protein-protein interactions involved in creating 
the HIVp dimer.  These crucial interactions can be incorporated into pharmacophore 
models to filter small molecules capable of dissociating the HIVp dimer. 
Finally, the last chapter is a completely novel idea to empirically distinguish the 
binding mechanism of dissociative inhibitors.  Hydrogen-deuterium exchange can 
determine the location dissociative inhibitors bind against the HIVp monomer, at 
concentrations and conditions similar to Zhang-Poorman kinetic assay.  The dissociative 
inhibitors will block natural hydrogen exchange within a deuterated solution, allowing us 
to determine the location of small molecule binding.  Coupled with high-resolution MD 
simulations, we can determine energetically favorable binding mechanism to block 
dimerization.  Medicinal chemistry can then be applied to find stronger inhibitors and 
allow the development of a potential generation of drugs targeting the HIVp dimer 
interface. 
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Chapter 2 
Development of MPS pharmacophore models of the HIV-1 protease dimer interface 
 
Introduction 
 HIV-1 protease (HIVp) is a 99 amino acid protein that forms a C2 symmetric 
homodimer.1  Each protease chain forms half of the active catalytic pocket, and an active 
protease is necessary for viral maturation and propagation.2  HIVp dimer interface is 
approximately 1800 Å2 in solvent accessible surface area (SASA).3  HIVp has a smaller 
contact surface than other typical protein-protein interactions (PPIs) but larger than the 
average of ~1700 Å2 for most homodimers.4   
Upon dimerization, 8.9-14.5 kcal/mol of Gibbs free energy stabilizes the 
homodimer under varying temperature, pH, and ionic conditions.5  Approximately 75% 
of the free energy lies in the interdigitating N- and C-termini, creating a β-sheet that 
composes half of the dimer interface contacts.6  The two termini of the HIVp monomer 
are highly dynamic, with fluctuations ranging from 5 to 9 Å.7, 8  Xie et al.9 reported a 
dissociation rate (KD) equilibrium of 5.8 µM between HIVp monomer and dimer at 
neutral pH, approximately one order of magnitude greater than the KD range reported by 
Todd et al.5  
The HIVp dimer interface is considered a potential therapeutic target for two 
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beneficial reasons.10  Failure to form a homodimer results in an inactive HIVp.  The 
symmetric active site contains two aspartic acids, one from each monomer, that are 
required for a general acid/general base reaction with water and the substrate.11  The 
second reason is the highly conserved nature of the dimer interface.12  Mutations in the 
interface region are deleterious to protease activity.9  Selective pressure from active-site, 
competitive inhibitors allows HIVp to mutate and escape drug efficacy.13  Targeting the 
dimer interface with small molecules has high therapeutic value and deserves attention as 
a simple, challenging model for studying other PPIs. 
In 1991, the first proof of dissociative inhibition was given by Zhang et al.,14 who 
used kinetic analysis and sedimentation equilibration to show that a C-terminal 
peptidomimetic could disrupt the HIVp dimer.  The kinetic analysis was based on a 
fluorescent-based assay, and the Zhang-Poorman assay has been used widely to 
discriminate the mechanism of HIVp inhibition.  Dimerization inhibitors fall into two 
classes: monovalent peptidomimetic inhibitors derived from the C-terminus and bivalent 
inhibitors mimicking the N- and C-termini with a linking region joining the two 
segments. Both strategies have led to submicromolar inhibition rates of dimerization, 
Ki,D.15   
Schramm and colleagues pioneered the monovalent class of inhibitors constructed 
from mimicking the C-terminus.16  The most effective inhibitors possess the common 
amino-acid motif of YEL, meant to displace residues 97-99 of the C-terminus.  The use 
of a palmytic acid extended from the N-terminus or a thryoxine moiety in place of the 
leucine improved dissociative inhibition rates to the low-nM range.17, 18  Frutos et al. 
performed an NMR structural study following the chemical shift perturbations with a 
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labeled [2-13C]-Trp residue.19  Labeled protein was followed upon addition of the dimer 
inhibitor Ac-SYEL-OH, titrated and monitored by 2D [1H-13C]-HSQC.  The inhibitor 
created chemical shifts at the Trp6 residue, indicating a change in the chemical 
environment near Trp6 upon ligand binding.  A model of the bound state was created 
using the 1HWR crystal structure, by removing the competitive inhibitor from the active 
site and truncating chain B to the C-terminal sequence of TLNF.  The backbone of the 
peptide inhibitor was taken from the C-terminal sequence, and Autodock 3 was used to 
optimize the orientations of the side chains. 
Caflisch et al. used the Multiple Copy Simultaneous Search method to 
computationally map chemical functionalities to the dimer interface.20  The study 
discovered a large, accommodating area normally occupied by the complimentary Phe99’ 
of the other monomer.  Their functional map suggested the incorporation of a thyroxine 
moiety into the peptidomimetic inhibitor synthesized by Dumond et al., which was 
subsequently found to increased the potency of the inhibitor.17  Their application of the 
Multiple Copy Simultaneous Search did not allow for the significant degree of flexibility 
inherent in the termini because restraints were placed on the protease.   
Bowman and Chmielewski developed bivalent, peptidomimetic inhibitors to 
mimic the dimer interface region occupied by both the N- and C-termini of the HIVp.21  
The two chains were optimized and linked together by a long, flexible alkyl chain.22  
SAR studies revealed that the optimal length to join the two was a 14-carbon, alkyl chain.  
Further refinement of the side chains in these bivalent inhibitors resulted in Ki,D ~30nM.23  
Reboud-Ravaux and coworkers recognized the entropic penalty associated with a long 
alkyl chain and constructed a bivalent inhibitor with a rigid linker, termed “molecular 
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tongs.”24  Geometries of the rigid linker were explored to create favorable interactions 
with the C-terminus, and derivatives were created to produce a non-peptidomimetic 
compound.25, 26 
To date, the mechanism of dissociative inhibition is confirmed through Zhang-
Poorman analysis.  Most of the compounds are peptidomimetic inhibitors derived from 
the termini, and it is assumed that they bind to a monomer of HIVp in the same fashion as 
the dimer contacts.  However, there is little evidence to confirm the structural 
complementarity between the dimer interface and the ligands targeting the region.  This 
makes any rational design of new inhibitors very difficult.  Improved inhibitors are 
needed because the existing inhibitors have unfavorable pharmacokinetic and toxic 
properties.27  They are very large peptides (>1000 MW) that are not appropriate for drug 
development.  If this mode of action is to ever become viable as a drug target, novel 
small molecules scaffolds are required.  
To the best of our knowledge, only two smaller inhibitors of dimerization have 
been found.  Simplified derivatives of didemnaketal A (an isolate from the sea squirt 
Ascidian didemnum) have a MW of 542 and inhibit HIVp in a dissociative mechanism 
with Ki,D ranging 2.1-29.9 µM.28  Schisanlactone A is a 464-MW natural product from 
the Vietmanese mushroom Ganoderma colossum that inhibits dimerization (Ki,D=17.5 
µM).29  (Some bile acids have weak activity but were incorporated into the peptidic 
inhibitors simply as rigid linkers.30) 
In this work, we have identified organic molecules under 500 MW with unique 
scaffolds that target the dimer interface, providing an important step toward more drug-
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like chemical space.  Our best inhibitors have affinities comparable to the natural 
products, but weaker than the large peptides.  We used computational methods to derive 
pharmacophore models of the dimer interface.  Molecular dynamics (MD) simulations 
were used to generate an ensemble of protein conformations for our multiple protein 
structure (MPS) method.  Each conformation of the ensemble was mapped with small 
molecule probes, and locations conserved across the majority of structures were used to 
identify consensus sites.  These sites were translated into pharmacophore models which 
were then used to identify small molecule inhibitors able to induce dissociative inhibition 
at the HIVp dimer interface.   
Using small molecules to disrupt PPIs is a challenging new pursuit with many 
medically relevant applications.31  Bcl-XL, gp120-CD4 and p53-MDM2 are a few 
examples of dissociative inhibition by small molecules at a PPI that are changing 
medicine.32-34  We hope that our pursuits may eventually lead to another example for the 
field. 
 
Methods 
Molecular Dynamics Simulations   
Several years ago, we published 3-ns MD simulations of the dimeric form of apo 
HIVp, based on very standard procedures.35  We initially used snapshots from that 
simulation to provide a proof of principle for our approach to identify inhibitors of 
dimerization.  We then extended the previous simulation to 30 ns to provide greater 
conformational sampling (using a combination of AMBER8 or 10 and the FF99SB force 
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field36-38).  We also calculated a 35-ns trajectory of the monomeric form of HIVp 
specifically for this study.  Protocols are detailed here. 
MD simulations of the monomer were performed using AMBER10 and the 
FF99SB force field.36-38  Initial atomic coordinates for the HIVp monomer simulation 
were obtained from the Protein Data Bank (PDB) repository (PDB ID: 1HHP).39  This 
was the same structure used to initiate the dimer simulations, except that the symmetry 
partner was not used for the monomeric state.  Hydrogen atoms were added via the 
AMBER tLEaP module.40  The +2e charge of the HIVp monomer was neutralized with 
the addition of two chloride ions.  The counter ions were placed 10 Å from the protein 
surface, guided by an electrostatic potential map calculated using APBS and its PyMOL 
plugin developed in house.41-43  The system was solvated with an octahedral box that 
extended 16 Å out from the protein surface in all directions; a closeness parameter of 0.5 
was used to place 10,836 TIP3P water molecules.44 
Minimization and equilibration of the solvated protein system occurred over a 
series of steps.  Hydrogen atoms, water molecules, and ions were first minimized while 
all non-hydrogen atoms of the protein were restrained.  Next restraints were removed 
from the side chains and the system further minimized, and finally, all restraints were 
removed and all atoms were minimized.   
In equilibration, SHAKE and 1-fs time step were used unless otherwise noted.  A 
10-Å vdw cutoff was used and PME boundary conditions were applied.45, 46  
Equilibration occurred in four steps: 1) Water and counter ions are heated from 10 to 310 
K under constant volume for 50 ps (time step = 2 fs).  During the temperature increase, 
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the remainder of the system was restrained (50 kcal/mol).  2)  Water and counter ions 
were then allowed to equilibrate at 310 K for another 10 ps while the restraints were 
maintained.  3) The protein was then allowed to heat from 10 K to 310 K in three, 10-ps 
steps under constant volume.  In the first three equilibration steps, the temperature 
increased from 10 K to 110 K, then 110 K to 210 K, and then 210 K to 310 K.  
Meanwhile, the restraints on the hydrogen atoms, water molecules, and counter ions were 
relaxed from 2 kcal/mol to 1 kcal/mol and, finally, to 0.5 kcal/mol.  4)  The system was 
then allowed to equilibrate at a constant pressure in a series of steps.  The first step was a 
10-ps equilibration with a restraint (0.5 kcal/mol) on all non-hydrogen atoms of the 
protein.  Next, the system was equilibrated for 10 ps with a weaker restraint (0.1 
kcal/mol) on the same atoms.  Last, the system was equilibrated for 2 ns while fully 
unrestrained.  The final production phase of the MD was run for 35 ns. 
The simulation was monitored and evaluated based on the RMSD of the protein 
fluctuations, calculated using AMBER’s ptraj program.40  The RMSD was based on Cα 
within the flap region (45-55), the N-terminus (1-4), the C-terminus (95-99), and the core 
(5-45 and 55-94).  The equilibrated structure was used as the reference state.  Secondary 
structure of the protease monomer was measured using the Dictionary of Protein 
Secondary Structure (DSSP) program.47   
Pharmacophore Design   
The MPS method for deriving pharmacophore models was previously applied to 
the active site of HIVp.48, 49  In this work, the same basic procedure was used, except that 
the focus was on surface of the dimer interface.  Structures for the initial pharmacophore 
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model were produced from snapshots of the previous 3-ns MD simulation.35  The initial 
0-ps frame, the 100-ps frame and every 300-ps snapshot afterward (until the 2800-ps 
structure) were selected for MPS.  Each chain in the dimer was separated, and the two 
monomers were both used independently for a total of 22 conformations representing one 
face of the symmetric dimer contacts.  Each structure was flooded with 500 small 
molecule probes (methanol, benzene, and ethane) in 16-Å radius sphere that 
encompassed the dimer interface.  The probes were minimized to the protein surface 
using a low-temperature, random-walk procedure called the Multi Unit Search for 
Interacting Conformers (MUSIC) which is implemented within the BOSS program.43  
The OPLS force field50, 51 was used, and the dielectric was set to 20 to reduce the 
attractive force of charge residues.  With a dielectric of 1, the methanol probes are 
strongly attracted to Asp 25 and important local, hydrogen-bonding minima can be 
missed.  The protein structures were held rigid during the minimization of the probe 
molecules. 
The minimized probes form clusters along the protein surface in each snapshot.  If 
the cluster contained ≥8 probes, a “parent” probe (the probe with the lowest energy in the 
cluster) was selected as a representative.  Each snapshot and its parent probes were 
overlaid to the equilibrated 1HHP structure, using a wRMSD alignment program.52  
Alignment of the structures resulted in clusters of parent probes, and represented 
“clusters of clusters”.  A consensus cluster was required to have parent probes from 
≥50% of the MPS.  Each consensus cluster was translated to a spherical pharmacophore 
element, centered at the average position of the parent probes (benzene centroid, ethane 
carbon-carbon bond midpoint, and methanol’s oxygen atom).  Each element’s radius was 
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based on the RMSD of those same features.  Benzene pharmacophore elements were 
labeled as aromatic.  Clusters with overlapping benzene and ethane probes were 
considered hydrophobic or aromatic in nature.  Methanol pharmacophore elements were 
classified a hydrogen-bond donor or acceptor based on the directionality of their 
interaction with the protein surface. 
Two pharmacophore models were derived from the longer simulations of the 
dimer and monomer of HIVp.  They were developed following the procedure above, 
except that the MPS were not taken from evenly spaced snapshots of the simulation.  For 
the longer simulations, the MPS snapshots were selected by clustering the MD trajectory 
into 10 representative conformations.  The means-clustering algorithm was employed and 
the dimer-interface residues were selected (all atoms of residues 1-6, 23-29, and 87-99).  
The dimer conformations were separated, and each chain was clustered into 10 
representative clusters to give 20 individual snapshots.  Snapshots from every 5 ps were 
used in the clustering. 
For the initial probe placement, the Cα of residue Thr26 was selected as the 
flooding center and the cutoff was a 15-Å radius.  Minimization was performed as 
previously described.  An all-atom wRMSD was performed to incorporate all of the 
significant flexible motion observed at the N- and C-termini.  A Jarvis-Patrick clustering 
program53 was used to group the probes.  Jarvis-Patrick parameters, j and k respectively, 
for each probe are as follows: 17 and 1 for benzene, 15 and 1 for ethane, and 17 and 1 for 
methanol.  The consensus clusters and pharmacophore elements were determined as 
described for the 3-ns model.   
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Lastly, a “core” pharmacophore model was developed to represent 
pharmacophore elements common to both the dimer and monomer data.  The core model 
was built by removing any elements from the dimer model that were not observed in the 
monomer model.   
Virtual Screening 
A computational database of ~34K compounds was generated for the chemical 
library of the University of Michigan’s Center for Chemical Genomics (CCG).  
Conformations for the compounds were pre-generated using OpenEye’s OMEGA 
program.54  A maximum of 300 conformations was allowed, with energy and RMS 
thresholds of 14 kcal/mol and 1 Å, respectively.55  The pharmacophores were compared 
to the database using the search query in the Molecular Operating Environment (MOE) 
program.56  Two means were used to relax the matching criteria and identify more 
compounds.  First, the radii of the elements were sequentially increased (1×RMSD, 
1.33×RMSD, 1.67×RMSD, 2×RMSD…), and second mismatches were allowed (fitting 
all elements, missing one element, missing 2 elements, etc).  Additional criteria (≤500 
MW, chemical diversity, commercial availability, etc) were used to prioritize the hits. 
Compound Screening 
 Before characterizing the inhibition mechanism, purchased compounds were 
screened in vitro for HIVp inhibition.  A fluorescence-based assay was used.57  The 
substrate was an oligopeptide, RE(EDANS)SQNYPIVQK(dabcyl)R, purchased from 
Molecular Probes (Cat. No. H-2930).  HIVp was originally purchased from Bachem 
Biosciences (Product H-9040) with larger quantities donated by Prof. Cecilia Schiffer of 
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the University of Massachusetts (both wild-type and multi-drug resistant strains of 
HIVp).  Compounds were purchased from Chembridge or ChemDiv and initially 
dissolved in DMSO at 5 mM or 10 mM concentrations.  Due to the low solubility of the 
compounds, PEG-400 was added to Buffer A (20mM phosphate, 1 mM DTT, 1 mM 
EDTA, 20% glycerol, 0.1% CHAPS and 0.1 % PEG-400 at pH 5.1) and Buffer B 
(100mM Sodium Acetate, 1M NaCl, 1mM EDTA, 1mM DTT 20% v/v Glycerol, 0.1% 
w/v CHAPS and 0.2% PEG-400 at pH 4.7).  Screened compounds were tested at a final 
concentration of 50 µM against 30 nM HIVp (final concentration) in either Buffer A or 
Buffer B.  The compounds were screened in duplicate after 40 minutes incubation.  The 
enzymatic reaction was initiated with 2 µM of substrate (final concentration), and the 
initial velocities of the reaction with putative dimer inhibitors were compared to 
uninhibited HIVp.  Compounds reported to inhibit HIVp by 25% or more were further 
characterized with the Zhang-Poorman assay.  The competitive inhibitor pepstatin A was 
used as a control. 
Zhang-Poorman Analysis 
The FRET-release assay of Zhang et al.14 was used to determine the inhibition 
rates and mechanism of action for the putative dimer disrupters.  Multiple fluorometric 
assays were performed, in triplicate, in 384-well, low-volume plates (Corning No. 3676) 
and read using a SpectraMax M5 from Molecular Devices.  The excitation/emission 
wavelengths of the substrate are 340/490 nm, and we employed a cutoff filter at 475 nm.  
The final concentration of compound was 40 μM (2 μL of compound diluted in water), 
and 8 μL of HIVp was diluted into Buffer A or Buffer B for a final concentration range of 
1-15nM or 5-50nM, respectively.  After 40 minutes of incubation at room temperature, 
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10 μL of substrate (6.1 μM final concentration) initiated the assay.  Fluorescence data 
was recorded in 1-minute intervals for 20 minutes at 37 oC.  A fourth-order polynomial, 
non-linear regression was used to fit the kinetic data.16  Initial velocities were calculated 
from the regression fit at the sixth minute and data was plotted according to Zhang-
Poorman.  Least-squares linear regression was used to fit the rearranged data, and 
dissociative inhibition rates, Ki,D, were determined from the y-intercepts.  The equation 
used was Ki,D = b0([I]/(b-b0)), where [I] is inhibitor concentration and b and b0 are the y-
intercepts in the presence and absence of inhibitor, respectively.  The competitive 
inhibitor pepstatin A was used as a control to distinguish competitive inhibition in the 
Zhang-Poorman plots (data not shown). 
 
Discussion and Results   
Initial MPS Model from the first 3-ns MD of the HIVp Dimer  
The 3-ns pharmacophore model was developed from our previous MD simulation 
of the dimer, based on the 1HHP crystal structure.48, 49  Snapshots of the protein were 
taken at 11 points in the simulation.  The dimer was split into its monomers, and the 
monomers were overlaid.  The consensus sites mapped by benzene, ethane, and methanol 
probes are shown in Figure 2.1.  
Within the MOE program,56 the pharmacophore model was used to screen 
Michigan’s CCG database.  The criteria were sequentially relaxed by increasing the radii 
of the elements and decreasing the number of elements required for a hit.  The number of 
hits for each combination of criteria is given in Table 2.1.  A total of 184 hits were 
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selected and clustered into 75% chemical similarity using MOE, which resulted in several 
sets that fell into three general shape categories: “spoked”, “rigid linear”, and “flexible 
linear”.  Representative compounds were chosen based on chemical diversity and 
availability for purchase.  A total of 12 compounds, four from each shape category, were 
purchased and screen in vitro in Buffer A.  Zhang-Poorman kinetic analysis was 
performed in Buffer A with a HIVp concentration range from 1-15 nM. 
 Three of the 12 compounds from the 3-ns model were found to inhibit HIVp.  
Indeed, Zhang-Poorman kinetic analysis showed the compounds to inhibit through a 
dissociation of the dimer.  The Ki,D inhibition rates were 13.4 (± 2.24) µM, 52.4 (± 2.23) 
µM, and 99.2 (± 4.05) µM for the compounds 1-3, respectively.  The assay results are in 
Figure 2.2.   
We were intrigued by the good affinity of compound 1, so we purchased four 
more compounds from the vendor that were most chemically similar to 1.  Of those, two 
were active with Ki,D of 38.6 and 42.9 μM , Figure 2.3.  Compounds 1, 4, 5, and 8 
(identified by the 30-ns model) constitute the largest family of molecules identified in 
this work. 
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A) B) Pharmacophore Model Based on the 3-ns MD of the Dimer 
Element Type x y z RMSD (Å) 
1 Aro/phobic 53.5953 45.1589 -2.3560 1.7277 
2 Aro/phobic 39.9640 51.0975 2.2804 2.2804 
3 Aro/phobic 49.7914 50.5249 6.5096 1.4436 
4 Aro 44.9667 54.9316 7.7915 1.7782 
5 Aro/phobic 50.4455 54.0263 -7.6683 1.8469 
6 Aro/phobic 48.3853 50.9182 -1.6079 1.2943 
7 Acc 54.0651 41.5045 -2.5040 1.8872 
8 Don 39.4232 52.7636 2.8752 1.2407 
9 Don 46.1961 49.5191 -1.1167 1.5183 
10 Don/Acc 49.4266 52.9248 -8.0318 1.2849 
 
Figure 2.1:  Coordinates and spatial representation of the MPS pharmacophore 
model based on the 3-ns MD simulation of the dimer.  A) The elements and 
coordinates are given relative to the 1HHP crystal structure.  B) The pharmacophore sites 
are shown with 1×RMSD radii, colored green for aromatic, cyan for 
aromatic/hydrophobic, blue for hydrogen-bond acceptor, and red for hydrogen-bond 
donor interactions.  The purple donor-acceptor site is buried behind the recessed 
aromatic/hydrophobic site at the center-bottom of the figure and is not visible from this 
orientation.  The protein surface is gray with the surface of the catalytic Asp25 colored 
black for reference.  The flap region is at the top, oriented toward the reader.  The active 
site lies between the flaps and Asp25.  The pharmacophore model maps the dimer 
interface below the active site.  The red element in the center of the figure, below Asp25, 
represents a hydrogen bond to Thr26 which is characteristic of the “fireman’s grip” motif 
of a hydrogen-bonding network shown to contribute to the stability of the dimer.58     
 
 
 
Table 2.1:  Number of hits obtained for in silico screening with the 3-ns model as the 
radii of the elements are increased and number of required features is reduced 
 Radii Multiplier Number of Elements Required for a Matching Hit 
 (#×RMSD) 10 of 10 9 of 10 8 of 10 7 of 10 6 of 10 5 of 10 
 1 0 0 0 0 78 3488 
 1.33 0 0 0 1 – – 
 1.67 0 0 2 188 – – 
 2 0 0 33 – – – 
 2.33 0 5 226 – – – 
 2.67 0 65 – – – – 
 3 7 – – – – – 
Total number of compounds considered (in bold italics above): 7+65+33+1+78=184 with duplicates  
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Figure 2.2:  Kinetic analysis of inhibitors identified with the 3-ns model of the 
dimer.  A screen of 12 compounds resulted in 3 inhibitors of HIVp.  The mechanism of 
dimerization inhibition was verified by Zhang-Poorman assay showing non-intersecting, 
near-parallel lines with the no-inhibitor control.  A) Compound 1, Ki,D = 13.4 µM.  B) 
Compound 2, Ki,D = 52.4 µM.  C) Compound 3, Ki,D = 99.2 µM.    
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Figure 2.3:  Dimerization inhibitors with similar scaffolds.  A and B)  The Zhang 
Poorman analysis and structure of compound 1.  D and F) Compounds 4 and 5 are 
chemically similar to compound 1.  C and E)  Kinetic analysis showed compounds 4 and 
5 to be dissociative  inhibitors with Ki,D values of 38.6 and 42.9 µM, respectively. 
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A) B) ) 
MPS Model from the 30-ns MD of the HIVp Dimer 
 The initial model was based on a very short MD simulation, pursued simply as a 
proof-of-concept.  That simulation is much too short by current standards.  Furthermore, 
extending the length of MD simulations can improve the results for MPS pharmacophore 
models, as reported by Meagher et al.48, 49 and Lerner et al.59  A 30-ns model, shown in 
Figure 2.4, was created by extending the previous MD simulation and using 
conformations representative of much greater conformational sampling.   
 
 
Pharmacophore Model Bases on the 30-ns MD of the Dimer 
Element Type x y z RMSD (Å) 
1 Aro 55.3167 39.6753 -3.2984 0.9308 
2 Aro/phobic 53.6327 45.5824 -2.6711 1.0854 
3 Aro/phobic 52.6310 48.0631 -1.1350 1.2316 
4 Aro/phobic 49.5117 50.0135 6.9862 1.0119 
5 Aro/phobic 41.2878 50.7591 2.8420 1.3449 
6 Don 56.4128 56.4714 10.0085 1.4511 
7 Don 57.0321 49.3395 1.6845 0.9405 
8 Don 54.2489 44.4524 -3.9576 1.2007 
9 Acc 54.7309 40.3557 -3.3089 1.2785 
10 Acc 53.4296 37.9627 -3.9918 0.9895 
11 Don 47.9795 36.7125 -1.0512 0.9032 
 
Figure 2.4:  Coordinates and spatial representation of the MPS pharmacophore 
model based on the 30-ns MD simulation of the dimer.  A) The coordinates are given 
relative to the 1HHP crystal structure.  B) The pharmacophore sites are shown with 
1×RMSD radii, colored green for aromatic, cyan for aromatic/hydrophobic, blue for 
hydrogen-bond acceptor, and red for hydrogen-bond donor interactions.  The protein 
surface is gray with the surface of the catalytic Asp25 colored black for reference.  The 
orientation is the same as in Figure 2.1. 
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The 30-ns model was used to filter the CCG library with in silico screening in 
MOE.  The number of hits under different selection criteria is given in Table 2.2.  
Compounds with MW >500 were eliminated, and a total of 108 compounds were 
considered.  The small molecules were clustered by 75% chemical similarity and 65% 
overlap in MOE.  A total of 55 compounds were purchased and screened in vitro in 
Buffer B.  The 30-ns pharmacophore model produced 7 compounds characterized as 
dimerization inhibitors by Zhang-Poorman in Buffer B, with a HIVp concentration range 
of 5-50 nM.  The kinetic analyses of compounds 6-12 are reported in Figure 2.5.  The Ki,D 
range for these seven compounds was 18.4-86.0 µM and the median Ki,D was 58.0 µM. 
All dissociative inhibitors from this study are summarized in Table 2.3. 
 
 
 
Table 2.2:  Number of hits obtained for in silico screening with the 30-ns model as 
the radii of the elements are increased and number of required features is reduced 
 Radii Multiplier Number of Elements Required for a Matching Hit 
 (#×RMSD) 11 of 11 10 of 11 9 of 11 8 of 11 7 of 11 6 of 11 
 1 0 0 0 0 0 490 
 1.33 0 0 0 0 20 2291 
 1.67 0 0 0 0 157 7152 
 2 0 0 0 7 603 – 
 2.33 0 0 0 30 1397 – 
 2.67 0 0 0 119 2450 – 
 3 0 0 1 316 3993 – 
Total number of compounds considered (in bold italics above): 1+119+20=140 with duplicates and no MW 
limit 
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Figure 2.5:  Kinetic analysis of inhibitors identified by 30-ns model.  The Zhang-
Poorman analysis for compounds 6-12 confirm a dissociative mechanism of inhibition.  
A-G) with Ki,D ranging 18.4-86.0 µM, see Table 2.3.  
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 Table 2.3:  Summary of inhibitors identified by the various MPS models.   
 Compound ChemBridge ChemDiv Inhibition MW Ligand Efficiency 
  Catalog Number Catalog Number Ki,D (µM)  (-log Ki,D / MW) 
From the 3-ns model 
 1  5594-3017 13.4 451.2 0.0108 
 2 5549891  52.4 538.3 0.0080 
 3 5472583  99.2 566.1 0.0071 
 4  1071-0033 38.6 501 0.0088 
 5  8002-9140 42.9 415 0.0105 
 
From the 30-ns model 
 6 5341525  18.4 440.2 0.0108 
 7 6138348  31.8 402.1 0.0112 
 8 5533247  36.6 431.5 0.0103 
 9 6249591  58.0 478.2 0.0089 
 10  K284-5225 69.1 434.2 0.0096 
 11  K284-5234 72.4 418.2 0.0099 
 12  C906-0998 86.0 469.3 0.0087 
 
From the Xtal model (presented further below)  
 none 
 
From the consensus model (presented further below)  
 13  C597-0141 100.7 438.2 0.0083 
 14  5056-0019 109.3 384.1 0.0103 
 15  3334-5637 123.6 422.1 0.0093 
 16 5565207  165.7 483.1 0.0078 
For comparison, in Lee and Chmielewski the ligand efficiencies for their best and smallest inhibitor are 
0.0048 and 0.0076, respectively.23  The natural products have ligand efficiencies of 0.0103 for 
schisanlactone A and a range of 0.0083-0.0105 for the simplified derivatives of didemnaketal A. 
 
 
Pharmacophore Model Generated from the 1HHP Crystal Structure 
Another pharmacophore model was created based solely on the complementary 
chain inherent to the 1HHP crystal structure (our so-called Xtal model).  Only a single 
monomer is present in the crystal structure, and its symmetry partner for the dimer (chain 
B) must be created by C2 rotation.  The Xtal pharmacophore was created in a way that 
represents traditional approaches to structure-based drug design.  As outlined in the 
introduction, many groups have created dimer inhibitors by building mimics of the 
termini of Chain B.  Here, we focused on the contacts between the cores of the 
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monomers, rather than the β-sheet region.  The most prominent characteristics of the 
interface were identified through inspection of the hydrogen-bonding patterns and the 
curvature of the hydrophobic vdw surface.  Highly curved surfaces indicated regions 
where deeper sub-pockets in Chain A were complemented by Chain B.  The atoms 
selected for the centers of the hydrogen-bonding elements were: the backbone oxygen of 
Leu5, the backbone oxygen of Trp6, the backbone oxygen of Leu24, the backbone 
nitrogen of Thr26, and the side-chain hydroxyl oxygen of Thr26.  These hydrogen-
bonding elements encode the “fireman’s grip” motif which has been shown to contribute 
to the stability of the dimer.58  The chemical properties of the elements were assigned 
accordingly (i.e., the backbone oxygens were defined as hydrogen-bond acceptors, the 
nitrogens were donors, and the hydroxyl group was either/both).  A 1.4-Å radius was 
used for all hydrogen-bonding elements of the model.  The Cγ of Leu5 and Cγ of Leu97 
were chosen for hydrophobic/aromatic centers, and a 2.0-Å radius was used to roughly 
parallel the radii used for hydrophobic carbons in molecular mechanics.  The Xtal model 
is given in Figure 2.6. 
 The Xtal pharmacophore model was used to computationally screen the CCG 
library in the same manner as the MD-based models, Table 2.4.  Of the 35 compounds 
considered, 24 were purchased based on availability and MW.  All were screened in vitro 
in Buffer B.  None of compounds from the Xtal pharmacophore model inhibited HIVp 
protease by either a competitive or dissociative mechanism.  This underscores the 
importance of incorporating protein flexibility in structure-based inhibitor discovery. 
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A) B) Pharmacophore Model Based on the Dimer Interface in the 1HHP Crystal Structure  (Xtal) 
Element Type x y z RMSD (Å) 
1 Aro/phobic 49.121 52.222 -1.577 2.0 
2 Aro/phobic 53.176 45.655 -2.295 2.0 
3 Acc 55.105 39.283 -3.738 1.4 
4 Acc 57.041 39.283 -3.786 1.4 
5 Acc 48.859 45.270 3.092 1.4 
6 Don 45.873 47.351 1.794 1.4 
7 Don/Acc 46.467 48.515 -0.579 1.4 
 
Figure 2.6:  The coordinates and spatial representation based on the symmetry 
partner in PDB 1HHP.  A) The coordinates are given relative to 1HHP.  B) The 
pharmacophore sites are shown with 1×RMSD radii, colored cyan for 
aromatic/hydrophobic, blue for hydrogen-bond acceptor, red for hydrogen-bond donor 
interactions and purple for hydrogen-bond acceptor/donor.  The protein surface is gray 
with the surface of the catalytic Asp25 colored black for reference.  The orientation is the 
same as in Figures 2.1 and 2.3. 
 
Table 2.4: Number of hits obtained for in silico screening against the Xtal model as 
the radii of the elements are increased and number of required features is reduced 
 Radii Multiplier Number of Elements Required for a Matching Hit 
 (#×RMSD) 7 of 7 6 of 7 5 of 7  
 1 2 309 3592+ 
 1.33 35 1978  
 1.67 507 5085  
 2 880 2091+  
 2.33 1808   
 2.67 3066 +   
Total number of compounds considered (in bold italics above): 35 with duplicates and no MW limit.  A 
plus sign (+) indicates the pharmacophore search was terminated early. 
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Multi-Drug Resistance HIVp 
Isolated from clinical HIVp infected patients, the multi-drug resistant (MDR) 
form of HIVp evades the efficacy of all inhibitors in clinical use.60  Bannwarth et al. 
tested the inhibition of competitive and dissociative inhibitors against wild-type and 
MDR forms of HIVp.25, 61  When compared to the competitive inhibitors, the dissociative 
inhibitors inhibited comparatively both forms of HIVp.  Since Bannwarth et al. 
demonstrated the comparative success in MDR and wild-type HIVp using 
peptidomimetic HIVp inhibitors, we wanted to demonstrate similar results for our PH4-
derived small molecule dissociative inhibitor. 
 The four best inhibitors from the 30-ns model, compounds 6-9, were selected for 
Zhang-Poorman characterization against MDR-HIVp.  Table 2.5 compares the Zhang-
Poorman results between the wild-type and MDR forms of HIVp.  Although the 
inhibition rates for the MDR form was approximately 2 to 4-folds greater than the wild-
type HIVp, that figure compares favorably to competitive inhibitors.  As reported in 
Banwarth et al., competitive inhibitors can lose several orders of magnitude in inhibition 
rates.25, 61 
Table 2.5: Comparison of Zhang-Poorman characterized inhibition rates between 
wild-type and MDR forms of HIVp. 
 Compound Zhang-Poorman assessed inhibition rates (Ki,d) 
 Number Wild-type (µM) MDR (µM) MDR:Wilt-type Ki,d Ratio 
 6 18.4 41.5 2.26 
 7 31.8 116.8 3.67 
 8 36.6 77.3 2.11 
 9 58.0 155.0 2.67 
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MPS Model Based on the MD Simulation of Monomeric HIVp   
 Our simulation of the HIVp dimer did not allow for any conformational 
rearrangement inherent to the monomeric state.  To incorporate this important physical 
information into our study, a 35-ns MD simulation of the monomer was initiated from the 
same crystallographic coordinates (1HHP).  The motion of the N- and C-termini was 
measured using RMSD from the equilibrated structure, shown in Figure 2.7.  The high 
degree of sampling for the termini was also observed by Levy and Caflisch7 and by Yan 
et al.8 in their simulations of the HIVp monomer.  Yan et al. described the N- and C-
termini forming a stable β-sheet in their simulations at 300 K.  The β-sheet is 
questionable, as Caflisch et al. did not report any stable secondary structure in their 
simulations.62  However, the two studies did agree that the termini were highly dynamic. 
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Figure 2.7:  RMSD of the monomer of HIVp.  The RMSD of the Cα over the course of 
the MD simulation is shown in black for the core of the monomer (residues 5-44 and 56-
94), in blue for the N-terminus (residues 1-4), in red for the C-terminus (residue 95-99) 
and in gray for the flap (45-55).  The average RMSD was 1.2, 9.6, 6.7, and 3.9 Å for the 
four regions, respectively. 
 
 Our own simulation shows the termini of the monomer significantly reorder and 
are much more variable than the relatively-stable core region.  The amplitude of motion 
at the termini ranges from 6 to 10 Å and appears to be more disordered than the mobile 
flap region.  The degree of flexibility is comparable to that observed by Yan et al. and to 
Levy et al. in their simulated monomeric protease.7, 8  
We calculated the secondary structure of over the course of our simulation using 
the DSSP program, and the results are presented in Figure 2.8.  The simulation of the 
monomer showed no stable secondary structure in the termini, agreeing with the findings 
of Levy et al.62   
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Figure 2.8:  Secondary structure of the monomer of HIVp over the course of the MD 
simulation.  The secondary structure was characterized using the DSSP program.  The 
termini of the 1HHP monomer remained largely unstructured. 
 
 To design a pharmacophore model from the MD simulation of the monomer, the 
trajectory was clustered into ten representative conformations using the ptraj module in 
the AMBER program.  The ten representative structures were used for our MPS 
procedure.  The procedure was the same as used for the other pharmacophore models, 
except that the Cα of Thr26 was selected as the center of the 15-Å radius sphere used for 
initial placement of the small chemical probes.  The model resulting from the 35-ns 
monomer simulation is described in Figure 2.9.  The CCG library was screened against 
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A) B) 
the pharmacophore model, see Table 2.6.  At this time, 125 compounds are being 
considered, and another lab member will test the purchased compounds. 
 
Pharmacophore Model Based on the 35-ns MD of the HIVp monomer 
Element Type x y z RMSD (Å) 
1 Aro 37.6358 48.8882 0.3348 0.7108 
2 Aro 48.8924 35.4444 -0.5960 0.5956 
3 Aro 50.3660 39.2816 1.9372 0.9924 
4 Aro/phobic 54.8234 43.3583 -1.8584 0.9539 
5 Acc 50.8056 54.9348 0.3424 1.308 
6 Acc 53.5527 38.1876 -4.6026 1.0672 
7 Acc 54.6076 43.3746 -2.6758 1.2281 
8 Acc 38.3942 48.5002 0.1560 1.1402 
9 Don 48.4316 36.5660 -0.6022 1.0618 
10 Don/Acc 56.1486 46.5532 0.5000 1.3553 
 
Figure 2.9:  Coordinates and spatial representation of the MPS pharmacophore 
model based on the 35-ns MD simulation of the monomer.  A) The coordinates are 
given relative to 1HHP.  B) The pharmacophore sites are colored green for aromatic, 
cyan for aromatic/hydrophobic, blue for hydrogen-bond acceptor, red for hydrogen-bond 
donor, and purple for hydrogen-bond acceptor/donor interactions.  The protein surface is 
gray with the surface of the catalytic Asp25 colored black for reference.  The orientation 
is the same as in the figures of the other pharmacophore models above. 
 
Table 2.6: Number of hits obtained for in silico screening with the 35-ns Monomer 
model as the radii of the elements are increased and number of required features is 
reduced 
 Radii Multiplier Number of Elements Required for a Matching Hit 
 (#×RMSD) 10 of 10 9 of 10 8 of 10 7 of 10 6 of 10 
 1 0 0 0 0 7 
 1.33 0 0 0 0 77 
 1.67 0 0 0 4 60 
 2 0 0 0 47 205 
 2.33 0 0 0 235 4719 
 2.67 0 0 0 820 8387 
 3 0 0 1 1830 12024 
Total number of compounds considered (in bold italics above): 1+47+77=125 with duplicates and no MW 
limit 
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A) B) 
A “Common Element” Pharmacophore Model 
 The “common” pharmacophore was developed to represent a core number of 
elements seen in both MPS models from MD simulations of the dimer and the monomer.  
It is possible that molecules which compliment both conformational states of HIVp 
would have an entropic advantage.  The model from the 30-ns MD of the dimer was used 
as the basis for the common pharmacophore.  The two models were compared, and 
elements were eliminated from the 30-ns model of the dimer if the element was not 
observed in both the dimer and monomer pharmacophores.  A hydrogen-bonding element 
near Asp29 was eliminated due to the distance from the other pharmacophore elements.  
The common pharmacophore model is shown in Figure 2.10. 
 
Pharmacophore Model of the Elements Common to both  
the Dimer and Monomer MPS Models 
Element Type x y z RMSD (Å) 
1 Aro/phobic 53.6327 45.5824 -2.6711 1.0854 
2 Aro/phobic 52.6310 48.0631 -1.1135 1.2316 
3 Aro/phobic 49.5117 50.0135 6.9862 1.0119 
4 Aro/phobic 41.2878 50.7591 2.8420 1.3449 
5 Don 57.0321 49.3395 1.6845 0.9405 
6 Don 54.2489 44.4524 -3.9576 1.2007 
Figure 2.10:  The “common” model based on 30-ns model of the dimer with 
elements eliminated when not observed in the monomer model.  A) The coordinates 
are given relative to 1HHP.  B) The consensus pharmacophore model is shown.  The 
view is rotated slightly so that all four aromatic/hydrophobic sites are visible. 
 
 The common pharmacophore was then used to filter the CCG compound library 
(Table 2.7), for a total of 208 total putative dissociative inhibitors (duplicates and high-
MW ligands removed).  After clustering the hits based on chemical similarity, a set of 
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115 compounds from this library were purchased and screened in vitro for inhibition in 
Buffer B.  Compounds found to inhibit HIVp were further characterized by the Zhang-
Poorman kinetic assay in Buffer B, with a HIVp concentration range of 5-50 nM.  Four 
compounds were characterized to be dissociative inhibitors.  The Ki,D for compounds 13-
16 are 100.7 (± 4.3) µM, 109.3 (± 8.1) µM, 123.6 (± 6.8) µM and 165.7 (± 10.4) µM, 
respectively.  The Zhang-Poorman analysis is shown in Figure 2.11. 
 None of the compounds from the resulting common model had low micromolar 
Ki,D.  The common model also resulted in fewer dissociative inhibitors compared to the 
30-ns model.  Despite being developed from the 30-ns model and filtering the same 
three-dimensional small molecule library, the common model performed worse than the 
30-ns model.  However, both models were able to selectively discriminate against 
competitive inhibitors.   
 
Table 2.7. Number of hits obtained for in silico screening with the common model as 
the radii of the elements are increased and number of required features is reduced 
 Radii Multiplier Number of Elements 
 (#×RMSD) 6 of 6 5 of 6 
 1 0 41 
 1.33 0 161 
 1.67 0 492 
 2 6 1458 
 2.33 20 2911 
 2.67 72 5139 
 3 254 7920 
Total number of compounds considered (in bold italics above): 72+161=233 with duplicates and no MW 
limit 
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Figure 2.11:  Consensus pharmacophore results.  A screen of 115 compounds resulted 
in four compounds that inhibited the dimerization of HIVp.  The mechanism of inhibition 
was characterized by the Zhang-Poorman assay.  A) Compound 13, Ki,D = 100.7 µM.  B) 
Compound 14, Ki,D  =109.3 µM.  C) Compound 15, Ki,D =123.6 µM.  D) Compound 16, 
Ki,D =165.7 µM. 
 
Conclusion 
 From simulations of the 1HHP dimer and monomer, we developed several 
dynamic receptor-based pharmacophores capable of identifying dimerization inhibitors 
from a virtual screen of a small molecule library.  Each pharmacophore was able to 
discriminate dissociative inhibitors over competitive inhibitors.  Although none of the 
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small molecules had sub-micromolar inhibition rates, they are approximately half the 
molecular weight of current bivalent compounds.  The small molecules are also non-
peptidomimetic.  Moreover, we showed the small molecules to be effective against the 
wild-type and MDR strains of HIVp.  Small molecules targeting the dimer interface are 
desirable to circumvent existing resistance seen in clinical therapy. 
 The number of higher affinity inhibitors can be limited the small molecule library, 
the MPS-derived pharmacophore description of the dimer interface, or the inherent 
difficulty in attacking the HIVp dimer interface with a small molecule.  The MPS 
pharmacophore models can be used to filter other small molecule libraries to search for 
better inhibitors.  Whether the dimer interface is well suited for inhibition by small 
molecules has not been determined.  The compounds in this study have undergone no 
optimization to better target the dimer interface.  The models can possibly be improved to 
incorporate more information from PPI “hot spots”.  Hot spots are patches along the 
protein surface that contribute disproportionally to oligomerization.63   
 This study demonstrates the MPS procedure can be used to target PPIs in a case 
where any “pocket” of the PPI is ill-defined.  We have previously targeted the p53-
HDM2 PPI and identified several novel chemical scaffolds.55  However, the p53-MDM2 
PPI is smaller (660 Å and 809 Å for MDM225-109 and p5317-29, respectively) compared to 
the HIVp dimer interface.64  The p53-MDM2 PPI also has a deeper binding cleft.  This 
study demonstrates the robustness of the MPS procedure against a more difficult PPI.  
With an estimated 650,000 PPIs in the human interactome, there is a significant 
probability that a number of druggable PPIs exist.65  It is exciting that the MPS procedure 
can be used to facilitate the pursuit of inhibitors to target PPIs.   
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Chapter 3 
Computational studies of the HIV-1 protease dimer interface complexed with 
dissociative inhibitors 
 
Introduction 
HIV-1 protease (HIVp) is an obligate dimeric homodimer protein with C2 
symmetry.1, 2  Zhang et al. created the first dissociative inhibitor targeting HIVp by 
creating a short, four residue peptide mimic, a peptidomimetic, of the C-terminus at the 
dimer interface.3  Based on the kinetic model of HIVp, Zhang also developed a 
fluorescent release, kinetic-based assay capable of discriminating between the two modes 
of inhibition: competitive and dissociative inhibition.  Sedimentation equilibration 
experiments were performed to confirm the dissociative mechanism and resulted in the 
observation of dimeric or monomeric forms of HIVp in the absence or presence of the 
dissociative tetrapeptide. 
Schramm et al. tested a series of compounds based on the N- and C-termini to 
determine the peptidimimetic core residues to efficiently inhibit HIV-1.4  Schramm et al. 
continued to increase HIVp dimer inhibition, refining the monovalent compounds based 
on the C-terminus, conjugating a palmitic acid lipid moiety to the N-terminus of his 
monovalent dissociative inhibitor.5, 6  In 2000, Calfisch et al. mapped the HIVp dimer 
interface using their Multiple Copy Simultaneous Search (MCSS) method.7  The MCSS 
method mapped a large and accommodating region normally occupied in the area 
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occupying symmetric residue Phe99’.  The MCSS map of the HIVp monomer allowed 
Schramm to incorporate a thyroxine moiety to the dissociative lipopeptide corresponding 
to the position Phe99’ would occupy, increasing ligand potency.8   
Investigators continued to optimize the monovalent dissociative inhibitor.  
Breccia et al. included a bicyclic guanidinium group to the N-terminus of the monovalent 
ligand, between the peptide and lipid moieties of the compound.9  The bicyclic 
guanidinium group is a positively charged molecule and its incorporation was designed to 
add a favorable interaction to the negatively charged C-terminus.  Bannwarth et al. varied 
the length of the palmitic acid in the dissociative lipopeptide and showed inhibition rates 
for dimer inhibitors were comparable for the wild-type HIVp and multidrug resistant 
protease MDR-HM (L10I-M46I-I54V-V82A-I84V-L90M) and ANAM-11 (L10I-M36I-
S37D-M46I-R57K-L63PA71V-G73S-I84V-L90M-I93L), unlike competitive inhibitors.10  
The ANAM-11 and MDR-HM HIVp variants are analogous to proteases found in multi-
drug resistant patients.11, 12 
In 1997, Zutshi et al. pioneered a novel set of bivalent compounds targeting the 
HIVp dimer interface.13  Zutshi cross-linked N- and C-termini derived peptidomimetics 
with an alkyl linker.  The cross-linking strategy generated the focus of Chmielewski’s 
group to produce bivalent compounds targeting the dimer interface.  Bowman et al. 
varied the linker length, changed linker moieties, and restricted the degrees of freedom 
within the alkyl linker; however, a 14 carbon alkyl linker produced the best dissociative 
inhibition.14  To reduce the size of the bivalent, Hwang and Chmielewski reduced each 
peptidomimetic chain to the core residues required to induce dissociation.15  Derivatives 
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of the bivalent dimer inhibitor increased potency of the compound, primarily through 
side-chain modification of the bivalent peptidomimetic.16, 17   
Recognizing the large entropic penalty associated with an alkyl linker, Bouras et 
al. created a set of ‘molecular tongs’.18  Molecular tongs are bivalent compounds with an 
aromatic group in the linking region.  Linker moieties included resorcinol, pyridinediol, 
or naphthalenediol as the restricting group.19  Dissociative inhibition rates were 
determined in the micromolar to submicromolar range.  A positively charged quinoline 
based linker was designed to restrict and create a favorable complement to the negatively 
charged C-terminus, and non-peptidomimetic chemical fragments mimicking amino acid 
side chains were created to increase affinity to the dimer interface.10  
To design stronger, more efficient inhibitors, more structural information 
regarding the relationship between the protein-ligand complex is needed. Frutos et al. 
attempted to describe the relationship using a [2-13C]-labeled Trp residue and 2D HSQC 
NMR.20  The Trp residue was chosen because only two Trp residues exist in each chain 
of the HIVp: Trp6 and Trp42.  When HIVp was exposed to the SYEL tetrapeptide, a 
dissociative inhibitor, NMR chemical shifts were observed with the labeled Trp6, within 
the dimer interface.  These chemical shifts indicated that the monovalent compound was 
bound near the Trp6 residue; however, the detailed mechanism of binding at an atomic 
resolution remains unclear. 
We feel computational modeling techniques can explain the binding mechanism 
and guide future medicinal chemistry efforts.  We decided to model dimer compounds 
derived from the Chmielewski group, due to the extensive and diverse library of 
compounds tested against HIVp.  Due to the peptide mimic nature of the bivalent 
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compounds, the initial coordinates for the protein-ligand computational model can be 
developed from the symmetry inherent in HIVp. 
 
Methods 
Ligand Construction   
The protein-ligand computational models were developed as described in 
Bowman et al. inhibition mechanism study of their dimer inhibitors.21  Ligands of interest 
are found in Figure 1, compounds (1) and (2).  We termed compound (1) as “Longest” in 
our study, due to the length of the compound and termed compound (2) as “Common” 
due to their choice to use the compound as a scaffold for derivatives.  The term 
“Northern” chain will refer to the N-terminal peptidomimetic portion and “Southern” 
chain will refer to the C-terminal peptidomimetic portion. 
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Figure 3.1:  ‘Longest’ compound construction.   A PyMOL generated image of the 
putative position of the N- and C-terminal peptidomimetics.  PDB: 1HHP is shown in 
cartoon format and the atoms (and coordinates) used to build the peptidomimetics are 
displayed in sticks. The symmetry partner of 1HHP was first generated and then atoms 
were trimmed to build the Longest compound.  One acetamide (ACE) residue was 
generated using the carboxyl of Gly94’ and the actyl chain continued through Ile93’.  The 
other ACE residue carboxyl group was added to the Pro1’ N-terminus. 
Design of Chmielewski’s Longest dimer inhibitor required preservation as much 
of the original PDB 1HHP dimer information, shown in Figure 2.1.  An acetamide (ACE) 
residue was added to the fixed Pro1 amide and the Gly94 carbonyl was replaced with the 
carbonyl for another ACE residue.  The carbon linker was built using the coordinates for 
the Gly94 backbone following to the alpha-carbon of Ile93.  The rest of the carbon linker 
was built around the C-terminus end of the 1HHP monomer and minimized in MOE, 
using the MMFF94x force field.  All other atomic coordinates were fixed within MOE 
during minimization. 
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Figure 3.2:  ‘Common’ compound construction.   A PyMOL generated image of the 
putative position of the N- and C-terminal peptidomimetics.  PDB: 1HHP is shown in 
cartoon format and the atoms (and coordinates) used to build the peptidomimetics are 
displayed in sticks. The symmetry partner of 1HHP was first generated and then atoms 
were trimmed to build the Common compound.  The two Ace residues were built using 
atoms from Ile3’ and Ile97‘, following the backbone through the side chain.  The acyl 
linker is shown in gray, lines representation. 
The same methodology for the Longest compound was applied to construct 
Chmielewski’s common compound.  The carbonyl groups for the two ACE residues were 
constructed using the coordinates for the carbonyl groups in Ile3 and Leu 97.  Ile3 and 
Leu97 have long side chains, helping to guide the linker chain.  Coordinates for Ile3 
atoms CA, CB, CG1, and CD1 were all used for the linker carbons.  Leu97 atomic 
coordinates for CA, CB, and CG were used to build the carbon linker over the C-
terminus.  The added linker carbon atoms were minimized within MOE, using the 
MMFF94x force field. 
Parameter Modification 
Modifications to Carr et al. AMBER94 force field parameters were needed to 
create the linker region in Chmielewski’s dimer inhibitors.22  The Ace residue was 
adapted due to similarity to the linker used by Chmielewski, shown in Figure 2.3.  The 
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ACE residue was modified by replacing a HC atom with a CT atom.  The previous 
charge on the HC atom was distributed to the original CT atom (-0.3662 to -0.2539 
charge).  The linker contained several CT (-0.2246 charge) atoms and 2 HC (0.1123 
charge) for every CT atom.  The linker was built over the C-terminus (buried side) and 
connected to another ACE residue conjugated to the peptidomimetic region.  The chain 
was allowed to minimize in MOE, using the MMFF94x force field while the remainder 
atoms were restrained from movement.23  
 
Figure 3.3:  ACE parameter modification.  A) The ‘Common’ inhibitor from Bowman, 
et al.  The hash boxes indicate the modified Ace residues.  B)  Carr et al. AMBER94 
force field ACE residue parameter was adapted to the construct the alkyl linker for 
Chmielewski’s two compounds.  A hydrocarbon was replaced with a cabon tetrahedral 
and the charge distributed to the original carbon tetrahedral.  A chain of carbon 
tetrahedrals and hydrocarbons, with the charge of -0.2246 and 0.1123 respectively, 
completed the alkyl linker. 
Protein and Ligand Preparation   
All-atom molecular dynamics (MD) simulations were performed using the 
AMBER8 or AMBER10 programs and the FF99SB force field.24-26  Initial atomic 
coordinates for the HIVp monomer simulation were obtained from the Protein Data Bank 
(PDB) repository (PDB ID: 1HHP).  Hydrogen atoms were added via the AMBER tLEaP 
module.27  The +2 electron charge of the HIVp monomer was neutralized internally with 
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the -2 charge of the longest ligand termini.  The system was solvated with a 16 Å 
octahedron solvation box, with a closeness parameter of 0.5 and TIP3P water.28  
Minimization and equilibration of the solvated protein system occurs over a series 
of steps.  Hydrogen atoms, water molecules, and ions are first minimized while 
everything else is restrained.  All-atoms, minus the restrained protein backbone atoms, 
are then minimized and, finally, all-atoms are minimized unrestrained.   
In equilibration, SHAKE and 1 fs is the time-step unless noted.  A 10 Å 
nonbonded cutoff is used and PME boundary conditions are applied.  Equilibration 
occurs in four steps: 1) Water and counter ions are heated from 10 to 310 K under 
constant volume for 50 ps (time-step = 2 fs).  During the temperature increase, the 
remainder of the system is restrained (50 kcal/mol).  2)  Water and counter ions are then 
allowed to equilibrate for another 10 ps while the remainder of the system is restrained 
(50 kcal/mol).  3) The protein is now allowed to heat from 10 K to 310 K in three, 10 ps 
steps under constant volume.  In the first three equilibration steps, the temperature 
increases 10 K to 110 K, then 110 K to 210 K, and last, 210 K to 310 K.  Meanwhile, the 
restraints on the hydrogen atoms, water molecules, and counter ions are relaxed from 2 
kcal/mol, then 1 kcal/mol and, finally, 0.5 kcal/mol.  4)  The system is now allowed to 
equilibrate at a constant pressure in a series of steps.  The first step is a 10 ps 
equilibration with a restraint (0.5 kcal/mol) on all atoms, except for hydrogen atoms, 
water molecules, and counter ions.  Next, the system is equilibrated for 10 ps with a 
weaker restraint (0.1 kcal/mol) on the previous atoms.  Last, the system is equilibrated for 
2 ns unrestrained.  The solvated protein system is now ready for the production phase of 
the trajectory. 
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Langevin Dynamics Preparation.   
The initial steps of LD setup are similar to MD setup.  HIVp atomic coordinates 
were obtained from the Protein Data Bank (PDB) repository (PDB ID: 1HHP).  
AMBER8 and FF99SB parameters were used to perform LD simulations.26  Hydrogen 
atoms were added during import into AMBER’s tleap program.  The aGBOBC(II) 
parameters were used for the Generalized Born approach to model the solvent 
implicitly.29  A 999 Å cutoff was used for non-bonded interactions, γ = 1 ps-1, 1 fs time-
step and no boundary conditions were used.  Default dielectrics were used: 78.5 for the 
exterior and 1 for the interior. 
Two minimization steps were required prior to equilibration.  Hydrogen atoms 
were minimized first, followed by an all-atom minimization.  The equilibration procedure 
is a series of steps to unrestrain the protein atoms and to ramp the temperature from 100 
to 300K.  The first equilibration step increased the temperature from 100 K to 200 K with 
restrain (2 kcal/mol) on all heavy atoms for 10 ps.  The second equilibration step 
increased the temperature from 200 K to 300 K with a reduced restrain (1 kcal/mol) on 
heavy atoms.  The following two equilibration steps further reduced the previous 
restraint, 0.5 kcal/mol followed by 0.1 kcal/mol, for 10 ps each.  Side chain atoms were 
released from the restraint, while the backbone atoms remained restrained (0.1 kcal/mol), 
for 10 ps.  Carbons in the linker region of Chmielewski’s dimer inhibitors were restrained 
in addition to the backbone atoms.  The last equilibration step included 300 ps of 
unrestrained production.  Ten separate 10 ns LD simulations were performed with unique 
seed numbers, for a total of 100 ns of LD production.   
94 
 
Trajectory Analysis 
 A root mean square deviation (RMSD) measures the degree of fluctuation when 
compared to a reference structure or an average position; however, RMSD is not a good 
measurement for dimer inhibitors.  The N- and C-termini in the HIVp monomer are 
dynamic, measuring an RMSD for the N- and C-termini of 6 and 8 Å, respectively, 
complicating an accurate measure of stability at the dimer interface.  The Multiscale 
Modeling Tools for Structural Biology (MMTSB) tool set and the MMTSB contact script 
determined ligand stability by measuring the ligand’s contact to the protein surface.30  
Contact, as defined by the MMTSB script, is a pair-wise inter-residue distance 
calculation of all pairs of heavy atoms less than 4.2 Å.  The contact script ascertained the 
percentage of contacts maintained over the course of a trajectory.  The initial coordinates 
of the built protein-ligand complex was defined as the reference structure.  The 
peptidomimetics were designed to mimic the peptides native to the original structure and, 
constitute the reference contacts. 
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Results and Discussion 
Molecular Dynamics Simulation 
 
Figure 3.4:  Northern and Southern Chains contact percentage from an MD 
simulation of the Longest compound.  Solid line indicates the Northern chain and the 
dotted line indicates the Southern chain.  The average percentage contact through the 
course of the trajectory for the Northern and Southern chains are 72.9 % and 85.4 %, 
respectively. 
 The MD simulation with the Longest compound complexed to the HIVp 
monomer in the dimer was ambiguous.  The dissociative inhibition rate, Ki,D, of the 
Longest compound was reported as 220 nM.  The stability of the ligand’s contact, plotted  
in Figure 2.4, of the Longest compound in simulation will reflect the inhibition rate.  The 
10 ns simulation showed the compound maintained contacts over the course of the 
trajectory, when compared to the putative binding mechanism; however, there is a caveat 
to the protein-ligand simulated complex.  It was undetermined if the stability seen in the 
MD simulation was a result of binding mechanism, or the low amount of sampling 
produced from a MD simulation.  A higher sampling method, such as a LD dynamic 
simulation, was decided as a more suitable method to determine if the stability was a 
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result of favorable complementary between the HIVp dimer interface and the Longest 
compound.   
Langevin Dynamic simulations 
 Ten separate LD simulations of the Longest and Common ligands complexed to 
the HIVp monomer were produced to parallel the MD simulation.  The Longest and 
Common compound were simulated to compare the stability of the two compounds.  The 
dissociative inhibition rate, Ki,D, of the Common compound was reported as 3.0 µM, 
higher than the Longest compound Ki,D of 220 nM.  We expected our ligand stability in 
our simulations to reflect the inhibition rates.  The perseverance of ligand contacts to the 
protein surface in the LD simulation will provide a metric to indicate inhibition rates. 
 
Figure 3.5:  Northern Chain percentage contact information for Longest and 
Common LD simulations.  (A) is a line graph of the Longest, Northern chain contacts 
over the course of the 10 independent LD trajectories.  B) is a histogram of the 
percentages in (A).  C) is a line graph of the Common, Northern chain contacts over the 
course of the 10 independent LD trajectories.  D) is a histogram of the percentages in (C).  
The average percentage for Northern Longest and Common chain contacts for all 10 
trajectories were 32.8 % and 50.5%, respectively. 
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 In Figure 3.5 (A) and (B), the contact percentage is detailed for the Longest, 
Southern compound’s ten LD trajectories. The histograms displayed in (B) and (D) is a 
graphical representation of the combined ten LD trajectory contact percentage 
distribution for all ten LD trajectories.  The Longest, Northern chain shows a bimodal 
distribution centered near 5 and 60%.  The average percentage for the combined ten LD 
trajectories contact percentages was approximately 33%.  The Common, Northern chain, 
Figure 3.5 (C) and (D), performed comparatively better compared to the Longest, 
Southern chain.  The Common, Southern chain displayed a unimodal distribution near 
50%.  Despite the tail in Figure 3.5 (D) towards the left, the average contact percentage 
for the Common, Nothern chain was 50%, better than the Longest, Northern chain. 
 
Figure 3.6:  Southern Chain percentage contact information for the Longest and 
Common inhibitor. (A) is a line graph of the the Longest, Southern chain contacts over 
the course of the 10 independent LD trajectories.  B) histogram of the percentages in (A).  
(C) is a line graph of the Common, Southern chain contacts over the course of the 10 
independent LD trajectories.  (D) histogram of the percentages in (C).  The average 
percentage for the Longest and Common Southern chain contacts for all 10 trajectories 
are 44.3% and 84.1%, respectively. 
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 In Figure 3.6 (A) and (B), the contact percentage is detailed for the Longest, 
Southern compound’s ten LD trajectories. The histograms in (B) and (D) plotted a 
graphical representation of the combined ten LD trajectories in (A) and (C), respectively.  
The Longest, Southern chain shows a unimodal distribution centered near 50%.  The 
average percentage for the combined ten LD trajectories contact percentages was 
approximately 44%.  The Common, Southern chain, Figure 3.5 (C) and (D), performed 
significantly better compared to the Longest, Southern chain.  The Common, Southern 
chain displayed a unimodal distribution near 80%. 
Alternative Binding Mechanism 
 The putative binding mode is not likely the binding mechanism measured in vitro.  
As stated earlier, the N- and C-termini are dynamic and there is a large entropic penalty 
for binding in the proposed mechanism.  The prospect of an alternative binding 
mechanism is a possibility.  Our simulations could discover an alternative binding 
mechanism, a rearrangement by either of the chains resulting in a more stable binding 
mechanism.  We can use the ligand contacts to search for a common HIVp surface region 
amongst the ten LD trajectories for the Longest and Common compounds.  If the 
Northern or Southern chain did uniformly rearrange, the ligands will share high 
agreement in the surface area contacts made on the HIVp dimer interface region. 
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Table 3.1:  A pairwise comparison of Longest, Northern chain contacts.  To check 
for agreement across LD trajectories of Chmielewski’s longest compound, a pairwise 
comparison of the Northern chain in the 9976 ps frame was performed.  Areas of 
agreement will share similar contacts and have high contact agreement.  Generally, there 
is little to no agreement amongst the frames when the contacts are compared across 
productions (Prod). Note: LD production 7 exited the dimer region entering the active site 
of HIVp. 
 
 Table 3.1, above, is a pair-wise comparison the contacts made by the Northern 
chain compound in the Longest compound.  The left side of the table is the reference 
structure being compared to by the top LD production frame.  The 9976 ps frame is being 
compared in all LD productions.  Across the table, there is low agreement in the contacts 
to the protein surface area.  LD production seven dissociated from the dimer interface and 
entered the catalytic pocket of the protease monomer. 
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Table 3.2:  A pairwise comparison of Longest, Southern chain contacts.  To check for 
agreement across LD trajectories of Chmielewski’s Longest compound, a pairwise 
comparison of the Southern chain in the 9976 ps frame was performed.  Areas of 
agreement will share similar contacts and have high contact agreement.  Generally, there 
is moderate agreement amongst the frames when the contacts are compared across 
productions (Prod).  Note: LD production 7 exited the dimer region entering the active 
site of HIVp. 
 
 In LD trajectories of the Longest inhibitor, the Southern peptidomimetic chain 
shares more of the HIVp dimer interface contacts than the Northern chain, shown in 
Table 3.2.  Besides LD production nine to LD production two and four, there is not a 
significant amount of uniformity across the trajectories to consider a consensus binding 
mechanism.  The Longest inhibitor modeled in the ten trajectories contact diverse areas 
along the protein surface. 
Table 3.3:  A pairwise comparison of ‘Common’, Northern chain contacts.  To check 
for agreement across LD trajectories of Chmielewski’s Common compound, a pairwise 
comparison of the Northern chain in the 9976 ps frame was performed.  Areas of 
agreement will share similar contacts and have high contact percentage.  There is high 
agreement in LD production (Prod) 6 with several of the reference structures. 
 
101 
 
In Table 3.3 above, the Common, Northern chain in the modeled ligand did not 
show uniformity across all frames; however, there was is a reasonable conformity 
amongst a few of the frames amongst the ten trajectories.  The frame for LD production 
six shares 100% of the surface contacts with the reference frames seven through nine, and 
reasonable agreement with LD production two; nonetheless, there would need to be more 
trajectories in agreement to declare the result represented the alternative binding 
mechanism seen in LD productions six through nine. 
Table 3.4:  A pairwise comparison of ‘Common’, Southern chain contacts.  To check 
for agreement across LD trajectories of Chmielewski’s Common compound, a pairwise 
comparison of the Southern chain in the 9976 ps frame was performed.  Areas of 
agreement will share similar contacts and have high contact percentage.  Generally, there 
is high agreement across all the production (Prod) runs. 
 
 The Common, Southern chain reported a high agreement across the frames, 
shown in Table 3.4.  The Common Northern and Southern chains in our ten LD 
simulations described a greater consensus in shared protease dimer interface contacts 
than the Longest compound.  There was not an apparent alternative binding mechanism 
in our LD simulations and our results contrasted with the empirical data.  There could 
still be an alternative binding mechanism, as the hypothetical binding mode is unstable at 
the termini, but our LD simulations of the Longest and Common inhibitor failed to find 
an alternative receptor pocket along the dimer interface. 
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Conclusions 
 Despite the initial MD results showing a high degree of stability by the Longest 
dissociative inhibitor, our LD results do not corroborate with the MD simulation.  The 
LD simulation allows a greater amount of sampling without the explicit water molecules 
present in the simulation.  If the ligand were to dissociate from the compound, as 
happened in the Longest simulation, the dissociation event would likely occur in LD 
simulation and not in MD.   
 The LD results were not as we predicted.  The Ki,D for the Longest inhibitor is 220 
nM and the Common Ki,D is 3 µM, at least one order of magnitude greater than the 
Longest inhibitor.  We expected the Longest inhibitor to show greater stability in LD 
simulations than the Common inhibitor.  Our results showed the opposite.  Not only did 
the Longest inhibitor failed to maintain contact on the HIVp dimer interface, they did not 
rearrange into a common binding mode.  The seventh trajectory of the Longest inhibitor 
had another unique distinction, it was the only trajectory out of the twenty total Longest 
and Common simulations in which the ligand dissociated from the dimer interface and 
entered the active site. 
 Although our simulations failed to reveal the protein-ligand relationship, we do 
know the inhibitors are not likely bound in the hypothesized, peptidomimetic mechanism 
as designed.  More structural information is needed to properly setup future simulations.  
Better structural information will help construct the compound’s initial atomic coordinate 
position for computational modeling.  The modeled dissociative inhibitors should then 
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find a favorable low energy well and relate the protein-ligand relationship at the dimer 
interface. 
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Chapter 4 
HIV-1 protease dimer stability: the role of critical residues to anchor the active 
protease dimer 
 
Introduction 
 A high replication error rate allows HIV-1 protease (HIVp) to easily escape drug 
efficacy and coupled with selective pressure produced from active site competitive 
inhibitors.1  The multi-drug resistant variants of HIVp necessitates alternative 
mechanisms to inhibit HIVp to fight the propagation of the HIV virion.  HIVp must 
dimerize to form an active catalytic site and the HIVp dimer interface is highly 
conserved.2, 3  These two features of the HIVp dimer interface create an attractive target 
to block the protein-protein interaction stabilizing the dimeric HIVp.  Dissociative 
inhibition of the HIVp originates from the creation of peptidomimetic compounds, 
derived from the N- and C-termini at the dimer interface.4, 5 
 The structural stability of the HIVp dimer interface was studied by Todd, et al.6  
Using differential scanning calorimetry, Todd characterized the Gibbs free energy 
resulting from dimerization.  At pH 5 and 298 K, the free energy gained from 
dimerization is 14.5 kcal/mol.  The interdigitating β-sheet at the dimer interface 
accounted for approximately 75% of the free energy gained upon dimerization.  Several 
of the residues in the C-terminus (Phe99, Asn98 and Leu97) were determined to be 
highly responsible for stabilizing the dimer interface.  Xie et al. studied HIVp 
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dimerization at a more physiological, neutral pH.  Xie reported the dissociative 
equilibrium constant of HIVp as 5.8 µM.7  Substrate or competitive inhibitor bound to 
HIVp shifted the equilibrium toward a catalytically active dimeric state.   
 Deletion of the last four residues in the C-terminus dissociates HIVp dimer to a 
monomeric state, as reported by Ishima, et. al, using NMR.8  This monomeric state of 
HIVp (HIVp1-95) was deposited in the Protein Data Bank repository (PDB: 1Q9P).  A 
stable monomer unit was predicted prior to Ishima’s work by Levy et al., after 
performing several Gō-model simulations to fold monomeric HIVp.9  
 Bogan and Thorn collected a database of alanine-substituted mutations involved 
in protein-protein interactions and the free energy differences on the stabilization of the 
protein-protein interaction.10  Their study found no correlation in buried residue surface 
area and free energy contribution.  Instead, Bogan and Thorn discovered what is now 
known as “hot spots” in protein-protein interactions.  Hot spots are unevenly distributed 
areas in the protein-protein interfaces, and contribute disproportionally to the free energy 
of protein-protein oligomerization.  These hot spots can be incorporated in the design of 
ligands to disrupt protein-protein interactions. 
 We know the free energy contributions to stabilize HIVp dimerization on a per 
residue basis, due to the work of Todd and colleagues; however, there is little information 
describing the interactions on the protein surfaces these residues are in contact with.  We 
will characterize the hot spot residue’s role within the dimer interface of HIVp and 
incorporate their contributions to create a pharmacophore based on mapped hotspots.  
Pharmacophores can be created by determining the density map of the residue’s position 
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through the course of a trajectory.  The pharmacophore chemical properties will be 
assigned according to the residue’s chemical property (i.e. Phe 99 is hydrophobic and 
aromatic).  A new pharmacophore based on the hot spot map of HIVp can filter a small 
molecule library complementing the properties of the hot spots or incorporated into 
previous pharmacophores (see Chapter 2). 
Using implicit solvent molecular dynamics simulations with a sufficient Langevin 
viscosity term (γ), we can sample the HIVp1-95 monomer from a dimeric form.11  The 
amount of sampling needed to dissociate HIVp will be determined by recreating the 
HIVp1-95 monomer in implicit solvent simulation.  The HIVp1-95 should provide a 
baseline trajectory length for further HIVp truncations or mutation we investigate. 
Methods 
Protein preparation and setup 
The initial steps of LD setup are similar to MD setup.  HIVp atomic coordinates are 
obtained from the Protein Data Bank (PDB) repository (PDB ID: 1HHP).  AMBER10 
and FF99SB parameters were used to perform LD simulations.12, 13  The aGBOBC(II) 
parameters were used for the Generalized Born approach to model the solvent 
implicitly.14, 15  A 999 Å cutoff was used for the non-bonded interactions, γ = 1 ps-1 for 
the Langevin equation, 1 fs time-step and no boundary conditions were used.  Default 
dielectrics were used: 78.5 for the exterior and 1 for the interior.   
The HIVp symmetry partner was generated to create a homodimer by the C2 symmetry 
operation in PyMOL.16   The last four residues in the dimeric 1HHP C-terminus were 
truncated to resemble a HIVp1-95 dimer.  The residues Cys95 and Cys95’ were 
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transformed with carboxyl termini and coordinates were then exported from PyMOL. The 
dimeric HIVp1-95 was imported into the AMBER8 tLEaP program and hydrogen atoms 
were added upon import.17, 18   
Two minimization steps were required prior to equilibration.  Hydrogen atoms were 
minimized first, followed by an all-atom minimization.  The equilibration procedure is a 
series of steps to slowly unrestrain the protein atoms and to ramp the temperature from 
100 to 300K.  The first equilibration step increased the temperature from 100 K to 200 K 
and had a restraint (2 kcal/mol) on all heavy atoms for 10 ps.  The second equilibration 
step increased the temperature from 200 K to 300 and a reduced restraint (1 kcal/mol) on 
the heavy atoms.  The next two equilibration steps further reduce the restraint, 0.5 
kcal/mol followed by 0.1 kcal/mol, for 10 ps each.  Side chain atoms were released from 
the restraint, while the backbone atoms remained restrained (0.1 kcal/mol), for 10 ps.  
The last equilibration step included 300 ps of unrestrained production.  Ten separate 20 
ns LD simulations were performed with unique seed numbers, for a total of 200 ns of LD 
production.   
Results and Discussion 
HIVp1-95 Simulations 
 A monomeric state of HIVp1-95 was previously characterized, PDB 1Q9P.8  We 
expected our simulations to result in a similar monomeric state after initially beginning in 
dimeric form, reproducing the HIVp1-95 monomer.   The C-terminal truncated HIVp1-95 
would serve as a baseline for other mutational HIVp variants and to explore regions of 
the dimer interface to map the interface hot spots.  Unfortunately, we did not reproduce 
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the monomer HIVp1-95 in all but one of our simulations.  Figure 4.1 below describes the 
measured distance between the two alpha carbons in the two catalytic Asp residues. 
 
Figure 4.1:  Distance between catalytic Asp Cα atoms in HIVp1-95 LD simulation.  
Ten LD dynamic simulations were produced modeling the C-terminal truncated HIVp1-95.  
LD production 3, indicated with the asterick (*), dissociated while the remainder LD 
trajectories continued as dimers.  For reference, the equivalent atom distance in PDB 
1HHP is 6.4 Angstroms. 
 Besides LD production 3, none of the remainder trajectories resulted in a 
monomeric HIVp1-95.  The third trajectory did demonstrate that our simulations of the 
dimeric HIVp1-95 can dissociate, but the amount of time needed for the remainder to 
dissociate is unknown.  The amount of computational hours needed for HIVp1-95 and any 
variant of HIVp to map protein hot spots can rapidly increase.  Following studies by 
Todd and colleagues on the stability of HIVp, there are several uncharacterized candidate 
residue interactions we could investigate.  Some previously characterized interactions, 
such as the inter- and intra-hydrogen bond network of Arg87-Asp29-Arg8’ described by 
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Louis, et al., do not need to be defined computationally; however, there are a number of 
important residues to consider.  The top six free energy contributors are Phe99, Asn98, 
Leu97, Leu5, Pro1 and Cys95, in that order.  We halted the investigation due to the large 
demand on computational time and the resources needed to accomplish the investigation 
to completion. 
Conclusion 
 A map of the protein hot spots at the HIVp dimer interface is still a worthy goal; 
although, a different strategy would be necessary.  A computational method, such as 
UMBRELLA sampling, could provide the detailed information needed and would result 
in a monomeric form of HIVp1-95 in silico.19  A distance restraint between the centers of 
each HIVp core, with the properties of a spring force, will produce free energy 
differences between the normal and truncated HIVp dimer.  The computational 
simulations will result in a monomeric protease because the restraint distance is user 
defined and will increase in length to force dissociation.  UMBRELLA sampling will 
map the energy landscape as the HIVp variants are dissociated and the free energy 
landscapes of the truncated protease variants can be compared to the wild-type HIVp.  
 
  
113 
 
References 
1. Preston B.D.; Poiesz, B.J.; Loeb, L.A., Fidelity of HIV-1 reverse transcriptase. 
Science 1988, 242, 1168-1171. 
 
2. Babe L.M.; Rose, J.; Craik, C.S., Synthetic "interface" peptides alter dimeric 
assembly of the HIV 1 and 2 proteases. Protein Sci 1992, 1, 1244-1253. 
 
3. Gustchina A. and Weber, I.T., Comparative analysis of the sequences and 
structures of HIV-1 and HIV-2 proteases. Proteins 1991, 10, 325-339. 
 
4. Franciskovich J.; Houseman, K.; Mueller, R.; Chmielewski, J., A systematic 
evaluation of the inhibition of HIV-1 protease by its C- and N-terminal peptides. 
Bioorg Med Chem Lett 1993, 3, 765-768. 
 
5. Schramm H.J.; Billich, A.; Jaeger, J.; Rucknagel, K.-P.; Arnold, G.; Schramm, 
W., The inhibition of HIV-1 protease by interface peptides. Biochem Biophys Res 
Commun 1993, 194, 595-600. 
 
6. Todd M.J.; Semo, N.; Freire, E., The structural stability of the HIV-1 protease. 
JMB 1998, 283, 475-488. 
 
7. Xie D.; Gulnik, S.; Gustchina, E.; Yu, B.; Wei, Shao; Qoronfleh, W.; Nathan, A.; 
Erickson, J.W., Drug resistance mutations can affect dimer stability of HIV-1 
protease at neutral pH. Protein Sci 1999, 8, 1702-1707. 
 
8. Ishima R.; Torchia, D.A.; Lynch, S.M.; Gronenborn, A.M.; Louis, J.M., solution 
structure of the mature HIV-1 protease monomer. J Biol Chem 2003, 278, 43311-
43319. 
 
9. Levy Y. and Caflisch, A., Flexibility of monomeric and dimeric HIV-1 protease. J 
Phys Chem B 2003, 107, 3068-3079. 
 
10. Bogan A.A. and Thorn, K.S., Anatomy of hot spots in protein interfaces. JMB 
1998, 280, 1-9. 
 
11. Zagrovic B.; Pande, V., Solvent viscosity dependence of the folding rate of a 
small protein: distributed computing study. J Comp Chem 2003, 24, 1432-1436. 
 
12. Case D.A.; Darden, T.A.; Cheatham III, T.E.; Simmerling, C.L.; Wang, J.; Duke, 
R.E.; Luo, R.; Crowley, M.; Walker, R.C.; Zhang, W.; Merz, K.M.; Wang, B.; 
Hayik, S.; Roitberg, A.; Seabra, G.; Kolossvary, I.; Wong, K.F.; Paesani, F.; 
Vanicek, J.; Wu, X.; Brozell, S.R.; Steinbrecher, T.; Gohlke, H.; Yang, L.; Tan, 
C.; Mongan, J.; Hornak, V.; Cui, G.; Mathews, D.H.; Seetin, M.G.; Sagui, C.; 
Babin, V.; Kollman, P.A. (2008), AMBER 10, University of California, San 
Francisco 
114 
 
 
13. Wickstrom L.; Okur, A.; Simmerling, C., Evaluating the performance of the 
ff99SB force field based on NMR scalar coupling data. Biophys J 2009, 97, 853-
856. 
 
14. Onufriev A.; Bashford, D.; Case, D.A., Modification of the generalized Born 
model suitable for macromolecules. J Phys Chem B 2000, 104, 3712-3720. 
 
15. Feig M.; Onufriev, A.; Lee, M.S.; Im, W.; Case, D.A.; Brooks III, C.L., 
Performance comparison of generalized born and poisson methods in the 
calculation of electrostatic solvation energies for protein structures. J Comp Chem 
2003, 25, 265-284. 
 
16. The PyMOL Molecular Graphics System, Version 1.2, Schrödinger, LLC 
 
17. Case D.A.; Darden, T.A.; Cheatham III, T.E.; Simmerling, C.L.; Wang, J.; Duke, 
R.E.; Luo, R.; Merz, K.M.; Wang, B.; Pearlman, D.A.; Crowley, M.; Brozell, S.; 
Tsui, V.; Gohlke, H.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Schafmeister, 
C.; Caldwell, J.W.; Ross, W.S.; Kollman, P.A. (2004), AMBER 8, University of 
California, San Francisco 
 
18. Pearlman D.A.; Case, D.A.; Caldwell, J.W.; Ross, W.S.; Cheatham III, T.E.; 
DeBolt, S.; Ferguson, D.; Seibel, G.; Kollman, P., AMBER, a package of 
computer programs for applying molecular mechanics, normal mode analysis, 
molecular dynamics and free energy calculations to simulate the structural and 
energetic properties of molecules. Comp Phys Commun 1995, 91, 1-41. 
 
19. Kumar S.; Rosenberg, J.M.; Bouzida, D.; Swendsen, R.H.; Kollman, P.A., The 
weighted histogram analysis method for free-energy calculations on 
biomolecules. 1. The method. J Comp Chem 1992, 13, 1011-1021. 
 
 
 
 
  
115 
 
 
 
 
Chapter 5 
Future Directions: Incorporating Hydrogen-Deuterium Exchange/ Mass 
Spectrometry Techniques to Determine Ligand Induced Dissociative Mechanism 
 
Introduction 
 As of this dissertation’s publication, there is no detailed structural information 
regarding the relationship between the HIVp dimer interface and small molecules causing 
dissociative inhibition.  All HIVp dimer inhibitors are characterized by the Zhang-
Poorman kinetic assay and published investigations were operating under the theoretical 
presumption based on the HIVp kinetic model.1  An NMR study by Frutos and co-
workers has shown a monovalent, C-terminal peptidomimetic inhibitor causes chemical 
shifts at the Trp6 residue; however, their docked simulation portraying the protein-ligand 
relationship is not conclusive evidence of the binding mechanism.2  We know that SYEL, 
C-terminal derived ligand is likely bound near the Trp6 residue, but greater atomic 
resolution is needed to thoroughly understand the protein-ligand relationship.  The 
relationship is necessary for building better, non-peptidomimetic inhibitors. 
 Our previous study modeled the protein-ligand interaction between the dimer 
interface and Chmielewski’s peptidomimetic derivatives, linked with an alkyl chain, were 
indeterminate regarding ligand binding.  Despite our computational models being 
inconclusive to illustrate the binding mechanism, the models did show the putative 
mechanism of binding to be unfavorable.  There is a large amount of disorder present at 
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the protease monomer interface.  The N- and C-termini accounted for approximately 6 
and 9 Å for the N- and C-termini, respectively, in our study (Chapter 2).  For the bivalent 
ligand to bind in an anti-parallel β-sheet with the protease monomer termini, there would 
be a large entropic penalty due to the degree of termini motions.  More empirical, 
structural information should result in more determinate computational models by 
providing better initial coordinates for future MD/ LD simulations.  Greater information 
regarding the ligand’s initial coordinates will position the ligand closer to its energetically 
favorable binding mechanism and permit better computational models to understand the 
protein-ligand relationship. 
 
Hydrogen-Deuterium Exchange 
 Hydrogen-deuterium exchange (HDX) coupled with mass spectrometry (MS) has 
gained popularity as a valuable analytical tool for the study of protein dynamics, protein 
folding, protein-protein interactions and protein-ligand binding.3  The principles of HDX 
are simple; any amide hydrogen atom along the protein backbone (minus proline 
residues) inherently exchanges with protons in solution (known as hydrogen exchange, or 
HX).  HX allows the incorporation of free deuterium atoms in solution (≥ 99% deuterium 
content) to interchange for hydrogen atoms, incorporating deuterium into the amide 
backbone.  The additional mass due to the deuterium atom can be resolved with MS and 
the location of the incorporated deuterium may be determined  by cleaving the protein 
into short oligopeptides.  
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 HX depends on the availability of the exposed amide hydrogen to exchange with 
the environment.  Exchange can occur quickly, within 1-10 seconds, for some amide 
hydrogens; however, HX can require longer incubation in solution (deuterated or not) if a 
domain motion or partial protein unfolding events is required to expose the amide 
hydrogen.  For a protein’s amide hydrogen to exchange with deuterium atoms the protein 
must be in a deuterated solution, obviously, but there are two methods to introduce 
deuterium for amide HX.  Choosing a method, dilution or rapid buffer switch, for 
deuterium introduction is determined by the MS and the instrument’s ability to identify 
small quantities of protein.   Dilution is the easier method of the two, involving the 
dilution of the protein in a deuterated solution.  Diluted samples may need to be 
concentrated after dilution prior to MS detection, typically in an HPLC column under 
high pressure.  In the rapid buffer switch approach, a protein solution is switched using a 
gel filtration spin column. 
 Dependent on the needs of the researcher, there are two methods (pulsed or 
continuous) to label the protein.4  The first method, pulse-labeling method, is frequently 
used for studies involving protein folding.  Since a protein folds rapidly, the best method 
to study protein folding is by slowly unfolding the protein.5  In a pulse-labeling 
experiment, a perturbant (i.e. urea or a change in pH) is added to the solution and 
equilibrated.  The perturbed protein, now in a partially unfolded state, may then be briefly 
deuterated labeling the newly exposed, less stable regions of the protein.6  To capture the 
multiple kinetic intermediates involved in protein folding, the perturbation, equilibration, 
deuteration and analysis steps would need to be iterated over several pertubant 
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concentrations.  Automation, such as a quench-flow scheme, of the pulse-labeling 
sequence of events may be required for analysis reproducibility.7  
 The second method, the continuous labeling method, is the more favorable 
method to label a protein because it is technically easier to perform.  Continuous labeling 
is used for slower transitions to unfolded states.  In continuous labeling experiments, a 
population of states exists within a mixture, allowing transitions from one state to another 
as a pertubant (pH change, urea, or a small molecule inhibitor) is added to the mixture 
and deuterated for several fixed intervals.  In theory, every state including intermediate 
states can be captured; however, the amount of sample in the low populated states will 
likely be too miniscule for accurate MS detection. 
 One problem naturally associated with HDX is the loss of deuterium label due to 
back-exchange.  Retention of the label can be assisted by change in solution conditions, 
such as freezing the sample or an acidic pH change; however, the amount of time 
between labeling and analysis remains a primary concern.  For electrospray ionization 
(ESI) loss of label can occur at the HPLC step; for matrix-assisted laser 
desorption/ionization (MALDI) experiments, loss of label occurs primarily during the 
sample preparation step.  Additional loss of the deuterium label can occur if a proteolysis 
step is included prior to analysis.  Several calculations may be performed to compensate 
for the amount of label loss, but the calculations do not significantly compensate for the 
information lost when compared to the initial deuterated sample.8 
 Protein fragmentation is used to help decipher the small, local changes a 
deuterium ion will cause.  To receive a higher spatial resolution, the labeled protein is 
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fragmented, often by proteases, into smaller fragments (5-10 residues) for analysis rather 
than using the whole labeled protein.  Since buffer conditions are acidic to discourage 
deuterium back-exchange, fragmentation is limited to acidic proteases.  Pepsin is the 
most common of these acidic proteases and other acidic proteases may be used; however, 
pepsin is still a more efficient protease.9  Pepsin is a non-specific enzyme, cutting along 
hydrophobic residues, but pepsin digestion is highly reproducible given equivalent 
proteolytic conditions.10, 11  Investigators tested multiple proteases to give smaller, 
overlapping fragments increasing spatial resolution.12  There are methods using non-
protease fragmenting techniques, but the methods are still in the development stage.13 
 For detection of the labeled protein, there are two major MS techniques that can 
be used to detect the labeled protein: ESI and MALDI.  More deuterium back-exchange 
occurs during MALDI analysis and the loss of deuterium causes the spectrum resolution 
to be less distinct and more difficult to interpret.14  In addition to the back-exchange 
problem, since there is no HPLC procedure prior to MALDI-MS, all peptide lengths are 
present concurrently in the MS and crowd the spectrum peaks.  Due to its disadvantages 
when compared to the ESI technique, MALDI is less commonly applied in HDX 
experiments. 
 ESI is a technique, similar to an aerosol and used to introduce a solvated protein 
system into a gas-phase environment for MS detection and analysis.  ESI applies a 
voltage through an emitter across a solution and emits the positively charged solution 
through a Taylor Cone as liquid droplets.15  The positively charged droplets will shrink in 
size, as the droplets evaporate, becoming a positively charged nanodroplet.16  As the 
nanodroplet continues to shrink in size, the positive charge of the nanodroplet will cause 
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the protein in solution to eject itself from the nanodroplet and into the gas-phase known 
as ion evaporation model (IEM).  In IEM, as the radius of the droplet decreases the field 
strength at the droplet surface becomes strong enough to cause desorption.17, 18  The 
protein, or peptide fragment, can then be detected by the MS detector. 
 MALDI is a two step process allowing the detection of biomolecules.19  The first 
step is the absorption of UV light emitted from a laser beam into the matrix solution.20  
The matrix solution is composed of biomolecules (the analyte), purified water, organic 
solvent (i.e. acetonitrile) and crystallized molecules (i.e. 3,5-dimethoxy-4-
hydroxycinnamic acid, 2,5-dihydroxybenzoic acid).21, 22  Absorption of the UV light 
causes ablation of the top layer of matrix solution.20  Ablation produces a plume with a 
mixture of matrix and analyte where the second MALDI step occurs, ionization of the 
solution.  The process of ionization is not completely understood.  Three hypothetical 
models exist: the photochemical ionization, the cluster ionization model, and the energy 
induced disproportionate model; however, each model lacks empirical validation.23  The 
ionized plume then undergoes the IEM and desorption process similar to the ionized 
nanodroplets in ESI, introducing the analyte to the gas phase. 
 Several protein binding interactions were characterized using HDX: protein-
protein interactions, protein-polypeptide, protein-nucleic acid, protein-lipid and protein-
small molecule.  Protein-ligand interactions determined by HDX include: the substrate- 
and inhibitor-bound Escherichia coli dihydrodipicolinate reductase, ATP-bound α-
crystallin and several ligand interactions with MAP kinases.24-26  Mapping ligand 
interactions with HDX is successful and can be extended to HIVp applications.  The 
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dimer HIVp protein is small, approximately 24 kDa, and the inherent C2 symmetry 
provides two monomer-dimer inhibitor interactions for every HIVp dimer.  
 
HIV-1 protease 
 Currently, there are no traditional biophysical methods to characterize the protein-
ligand relationship.  The intrinsic entropy at the N- and C-termini in the dimer interface 
creates a large amount of disorder for X-ray diffraction patterns for crystallographic 
efforts.  NMR has solubility issues associated with the ligands.2  The computational 
simulations previously presented in this dissertation failed to converge on a consensus 
binding mode for Chmielewski’s dissociative inhibitors.  There is a growing amount of 
research which coupled low- to medium-resolution experiments with other biophysical 
techniques, hybridizing the results, and creating a structural model from the combined 
information.27    
HDX is well suited as a technique to characterize the binding mechanism of 
protease dissociative inhibitors.  The protease monomer is small, 11.8 kDa in size, and 
the inherent symmetry of HIVp homodimer will provide twice the monomer structural 
information per a dissociative event.  MS benefits from accurate sample detection at low 
concentrations (nM), similar to those used in vitro assay conditions.  The dimer interface 
contains several amides in the dimer interface that will be exposed for HX in solution 
upon dissociation.  The N- and C-termini, normally hydrogen-bonded in an 
interdigitating β-sheet, will become more exposed upon dissociative inhibition.  Active 
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site residues, associated in the hydrogen-bonding network described as the “Fireman’s 
Grip”, will also become unprotected and available for HX.28 
 The method may provide structural information to characterize the binding 
mechanism for future allosteric inhibitors.  Inhibitors targeting the “cheek” and “eye” 
regions of HIVp currently do not have empirical structural validation.29, 30  A recent study 
by Chang et. al. is an example of allosteric inhibition of HIVp without structural 
validation.31  Chang and colleages performed a library screen against wild-type and a 
mutant strain of HIVp.  The library screen resulted in one compound shown to inhibit 
HIVp a series of assays (Michealis-Menten, and Yonetain-Theorell assays) suggesting 
the compound inhibits through an allosteric mechanism.  The authors eliminated a dimer 
inhibition as the mechanism for their reported compound, by comparing similar IC50 
values between the monomeric form of HIVp and the IC50 value for the dimeric HIVp.  
Recognizing the cheek region as site for allosteric control, as reported by Perryman and 
coworkers, Chang and colleagues then performed computational docking experiments 
against the allosteric groove.  As of publication of this dissertation, there is no structural 
validation of the bound protein-ligand relationship for the compound. 
 Protein-protein and protein-ligand interactions HDX studies are immediately 
related to our interests; however, HDX studies can be extended to include HIVp 
monomer folding.  Computational simulations of HIVp monomer folding were conducted 
by Levy et. al.  Levy found two regions, term local elementary structures (LES), 
responsible for stabilizing the HIVp monomer.32  Broglia, et. al. attempted to block 
monomer folding by developing peptidomimetics based on the LES peptides, 
destabilizing the HIVp monomer.33  A circular dichroism spectroscopy experiment and 
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Lineweaver-Burk kinetic analysis was performed to suggest the inhibition mechanism 
was due to monomer unfolding; however, there is no direct structural evidence of the 
protein-ligand relationship. 
Protein-protein, protein-ligand and protein-folding are all areas HDX can 
contribute structural information.  The potential for hydrogen-Deuterium Exchange/Mass 
Spectrometry applies towards HIVp is large due to its therapeutic and scientific value.  
The significance of the work can contribute to future generations of HIVp inhibitors and 
prevent affecting inhibitor binding without adversely influencing HIVp enzymatic 
activity by destabilizing the dimeric protease fold.   
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A) 
 
 
 
Appendix 
Alternative Pharmacophore Model 
 
Supplemental information from Chapter 2 
Simplified pharmacophore model 
 
Figure A.1:  Coordinates and diagram of the MPS pharmacophore model based on 
the “Simplified” model.  A) The elements and coordinates are given relative to the 
1HHP crystal structure.  B) The pharmacophore sites are shown with 1×RMSD radii, 
colored cyan for aromatic, green for aromatic/hydrophobic, blue for hydrogen-bond 
acceptor, and red for hydrogen-bond donor interactions. 
 The simplified model, Figure 2.12, eliminated the hydrogen-bond donor to Thr26 
in the 3-ns model, Figure 2.1(B).  The element was eliminated due to it proximity to the 
binding site.  The goal was to shift the focus toward the elements at the core of the 
binding interface.  The same in silico screening procedure was used within the MOE 
program.  A total of 288 hits were identified and clustered into three very general 
“Simplified” 3-ns MPS Pharmacophore Model 
Element Type x y z RMSD (Å) 
1 Aro|Hyd 53.5953 45.1589 -2.3560 1.7277 
2 Aro|Hyd 39.9640 51.0975 2.2804 2.2804 
3 Aro|Hyd 49.7914 50.5249 6.5096 1.4436 
4 Aro 44.9667 54.9316 7.7915 1.7782 
5 Aro|Hyd 50.4455 54.0263 -7.6683 1.8469 
6 Aro|Hyd 48.3853 50.9182 -1.6079 1.2943 
7 Acc 54.0651 41.5045 -2.5040 1.8872 
8 Don 39.4232 52.7636 2.8752 1.2407 
9 Don|Acc 49.4266 52.9248 -8.0318 1.2849 
B) 
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chemical families.  Twelve compounds were purchased for in vitro testing.  Two weak 
inhibitors were identified, and the mechanism of dimerization inhibition was verified by 
Zhang-Poorman kinetic analysis, results in Figure 2.13 below. 
 
Figure A.2:  ‘Simplified’ pharmacophore results.  Testing of 12 compounds identified 
two inhibitors of HIVp which both targeted dimerization.  A) The Zhang-Poorman 
analysis of compound ‘A’ resulted in a Ki,D of 122 µM.  B) The assay of compound ‘I’ 
resulted in a Ki,D of 127 µM.   
 
Center for Chemical Genomics (CCG) and Pharmacophore Screening Results.  The 
following tables are the filtered results for each pharmacophore table, reported in Table 
2.5.  The table indicates the criteria used in the pharmacophore search for a small 
molecule to match the pharmacophore elements.  Bold and italicized numbers are the 
conditional sets we further clustered by chemical similarity. 
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Table A.1:  Number of hits obtained for in silico screening with the 3-ns model as 
the radii of the elements are increased and number of features is reduced 
 Radii Multiplier Number of Elements 
 (#×RMSD) 9 of 9 8 of 9 7 of 9 6 of 9 5 of 9 
 1 0 0 0 2 1328 
 1.33 0 0 0 30 – 
 1.67 0 0 6 674 – 
 2 0 0 95 3016 – 
 2.33 0 18 549 – – 
 2.67 3 151 3830 – – 
 3 12 714 – – – 
Total number of compounds considered (in italics above): 12+151+95+30=288 with duplicates 
 
 
